Leave a comment

CHAPTER 92 MYELODYSPLASTIC DISORDERS (INDOLENT CLONAL MYELOID DISEASES AND OLIGOBLASTIC LEUKEMIA)

CHAPTER 92 MYELODYSPLASTIC DISORDERS (INDOLENT CLONAL MYELOID DISEASES AND OLIGOBLASTIC LEUKEMIA)
Williams Hematology

CHAPTER 92 MYELODYSPLASTIC DISORDERS (INDOLENT CLONAL MYELOID DISEASES AND OLIGOBLASTIC LEUKEMIA)

MARSHALL A. LICHTMAN
JAMES K. BRENNAN

Definition and History

History

Classification
Etiology and Pathogenesis

Etiology

Pathogenesis
Clinical Features

Incidence by Age, Sex, and Familial Occurrence

Symptoms and Signs

Special Clinical Features
Laboratory Features

Blood

Plasma Abnormalities

Marrow

The 5Q-Syndrome

Monosomy 7 Syndrome
Specific Clonal Myeloid Syndromes

Acquired Idiopathic Sideroblastic Anemia

Acquired Idiopathic Nonsideroblastic Anemia

Multilineal Cytopenia with Hypercellular Marrow
Uncommon Preleukemic Syndromes

Isolated Thrombocytopenia

Isolated Neutropenia

Monocytosis

Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, and Eosinophilic Fasciitis
Oligoblastic Leukemias

Definition and History

Oligoblastic Leukemia (Refractory Anemia with Excess Myeloblasts)

Treatment, Course, and Prognosis

Stem Cell Transplantation

Course and Prognosis
Prodromal Syndromes Antedating Lymphocytic Leukemia
Indolent Clonal Myeloid Disorders or Oligoblastic (Myelogenous) Leukemia Preceding or Emerging in Lymphoid Malignancies other than Acute Lymphocytic Leukemia
Chapter References

In contrast to florid acute myelogenous leukemia, there are a group of neoplastic (clonal) myeloid disorders that range from non-progressive to more slowly progressive than AML. The disorders may appear in childhood, but the incidence increases exponentially after age 50 years, and most cases occur between 60 and 90 years of age. These disorders range from acquired idiopathic anemias with or without ringed sideroblasts to oligoblastic myelogenous leukemia. The diseases share a propensity to cytopenias and multilineage dysmorphogenesis of blood cells. Red cells often have striking poikilocytosis, anisocytosis, anisochromia, and stippling. The marrow usually contains increased erythroid precursors with dysmorphic features and nuclear and granular anomalies in neutrophils associated with increased granulocyte precursors. Giant or microcytic platelets, often with abnormal granulation, in the blood are associated with megakaryocytic hyperplasia and atypical lobulation and size of megakaryocytes in the marrow. In the nonprogressive syndromes, anemia is accompanied by only slight variations in neutrophil and platelet levels, and blast cells are not increased in the marrow. Clonal cytogenetic abnormalities occur, however. The syndromes may follow radiation or chemotherapy for another malignancy. In the more progressive syndromes, leukemic blast cells are increased, cytopenias are more severe, and the disease has high morbidity and mortality from infection and bleeding. In each of the syndromes, there is a propensity to evolve into frank AML ranging from about 10 percent in the idiopathic anemias to about 40 percent of patients with trilineage cytopenias and increased marrow blast cells. Mortality from infection also is a high risk in those with severe leukopenia. In the most indolent forms, therapy may not be required. Therapy with cytotoxic drugs, red cell or platelet transfusion, antibiotics, and hematopoietic cytokines may palliate the disease when it is progressive (oligoblastic leukemia). In young patients allogeneic stem cell transplantation may be very useful.

Acronyms and abbreviations that appear in this chapter include: ALIP, abnormal localized immature precursors; ALL, acute lymphocytic leukemia; AML, acute myelogenous leukemia; ATRA, all-trans retinoic acid; CFU-BL, blast cell progenitors; CFU-GM, colony-forming units for granulocytes and monocytes; GM-CSF, granulocyte-macrophage colony-stimulating factor; IRF-1, interferon regulatory factor 1; LE, lupus erythematosus; M-CSF, monocyte colony-stimulating factor; MCV, mean cell volume; NF1, neurofibromatosis; RAEB, refractory anemia with excess blasts; RAEM, refractory anemia with excess myeloblasts; SCF, stem cell factor; WT1, Wilm’s tumor.

DEFINITION AND HISTORY
Myelodysplasia is a term used to encompass a spectrum of clonal (neoplastic) myeloid disorders marked by ineffective hematopoiesis, cytopenias, qualitative disorders of blood cells and their precursors, and a variable predilection to undergo clonal evolution to florid AML. The disorders range from relatively indolent idiopathic anemias, with a relatively lower frequency of progression to AML, to more troublesome clonal multilineage cytopenias, to oligoblastic myelogenous leukemias that often progress into overt AML. The somatic mutation that leads to these disorders arises in a multipotential hematopoietic cell. Dysplasia is a term that classically implies a polyclonal and, therefore, nonneoplastic process. The choice of the term myelodysplasia to denote clonal (neoplastic) disorders is unfortunate because it is hard for students and patients to understand its relationship to other clonal stem cell disorders such as idiopathic myelofibrosis that can have all the features of “myelodysplasia” but are ignored in its classification. Moreover, drawing diagnostic distinctions among 10, 20, and 30 percent leukemic blast cells is inconsistent with the biological behavior of cancer and medicine’s classification of cancer. The term myelodysplasia is, however, widely used.1,2 and 3
The term indolent clonal myeloid disease, or hemopathy, refers to neoplasias arising in a multipotential hematopoietic marrow cell that result in diseases with no discernible leukemic blast cells in the marrow or blood (e.g., acquired idiopathic anemias) or in oligoblastic leukemia in which an increased number of (leukemic) blast cells is present in the marrow but in which, untreated, the course is smoldering or subacute in contrast to AML.
The boundary between acquired idiopathic anemia and oligoblastic myelogenous leukemia may be indistinct because of the insensitivity of the marrow examination; however, continued observation clarifies the situation. If leukemic blast cells are evident in marrow, the diagnosis of oligoblastic leukemia can be made, maintaining the principle that the histopathologic diagnosis should depend on the presence or absence of tumor cells, not the rate of progression or severity of the manifestations of the malignancy. The proportion of marrow myeloblasts is not increased in reactive states, for example, granulocytic hyperplasia as a result of infection, noninfectious inflammation, solid tumors, and drug-induced granulocytosis (e.g., glucocorticoids, lithium). Indeed, the proportion of blasts usually falls to less than the normal value of 1.0 ± 0.4 SD percent. It is rare to have more than 2.0 percent myeloblasts in a normal marrow in older children and adults, and higher proportions, for example, over 3 percent, are virtually confined to cases of oligoblastic leukemia. The one exception to this rule is that some patients treated with granulocytic growth factors may have a slight increase in blast cells.
The clonal proliferation of multipotential hemopoietic cells is accompanied by variable effects on all blood cell lineages and is usually associated with pathologically enhanced apoptosis of marrow precursor cells such that leukopenia and thrombocytopenia of varying severity often accompany the anemia. Qualitative abnormalities of cell shape, organelle structure, biochemical pathways, and function can occur. The range of clinical expression is broad. Thus, clonal myeloid hemopathies can occur with isolated anemia and a nearly normal-appearing marrow or with severe pancytopenia, profoundly hypercellular marrow, and alterations in blood cell shape, size, and function. The more profound the disorder, the more likely oligoblastic leukemia will be discovered on marrow examination. Since leukemic blast cells may not be evident and some patients with clonal hemopathies do not develop overt leukemia (although their risk is several-thousand-fold that of unaffected individuals), the designation myelodysplasia has been applied. The choice of the term was intended to highlight the striking dysmorphic appearance of blood and marrow cells neglecting the central alteration, neoplasia. As currently used, myelodysplasia encompasses syndromes that are frankly leukemic, such as so-called refractory anemia with excess blasts.4 Indeed, many of the affected individuals have myelogenous leukemia that is more indolent (smoldering) than overt AML.
HISTORY
At the beginning of the twentieth century, reports of highly morbid cytopenic disorders, refractory to treatment, began to appear in the medical literature.3 Chevallier and colleagues, in 1942, discussed formally the “odo-leukemia.”5 They chose the Greek word odo, meaning threshold, to highlight disorders that are on the threshold of leukemia. Chevallier proposed leucoses as the generic term for leukemias so that marked variations in white cell counts and other presenting features would not engender inappropriate terminology. It was a sage but neglected proposal.
In 1949, Hamilton-Paterson used the term preleukemic anemia to describe patients with refractory anemia antecedent to the development of AML,6 and in 1953, Block and coworkers expanded the concept to include cytopenias of all lineages and described cases that closely fit with our current concepts of a clonal myeloid hemopathy prior to the evolution to overt AML.7 Thus, by midcentury, the relationship of acquired idiopathic cytopenias to the subsequent onset of AML had become broadly appreciated.8,9,10,11,12,13,14 and 15 Terms such as herald state of leukemia, refractory anemia, sideroachrestic anemia, idiopathic refractory sideroblastic anemia, pancytopenia with hyperplastic marrow, and others were coined to describe the various manifestations of the hematopoietic derangement that preceded the onset of AML.
In 1975, at a conference on unclassifiable leukemias held in Paris, Marcel Bessis, Jean Bernard, and others suggested the term hemopoietic dysplasia, later shortened to myelodysplasia for the group of disorders that had a more indolent course than AML.16,365
CLASSIFICATION
One classification scheme,2 which is now undergoing change, separates myelodysplastic syndrome arising de novo into several subsets: refractory anemia (with other cytopenias implied), refractory anemia with ringed sideroblasts (with other cytopenias implied), and refractory anemia with excess blasts (smoldering myelogenous leukemia).2 Chronic myelomonocytic leukemia, although proposed as a myelodysplastic syndrome, can also be included among the chronic myelogenous leukemias17 (see Chap. 94). The designation refractory anemia with excess blasts in transformation has been dropped, since it conveys no additional diagnostic or prognostic information. The myelodysplastic syndromes include entities that have marrow blast percentages ranging from less than 2 percent in refractory anemia to over 20 percent in refractory anemia with excess blasts.2 This approach is unfortunate, since in no other neoplasms is the designation of the cancer, in this case myelogenous leukemia, called by another name when there is more or less of the tumor cells present. Thus, myelogenous leukemia, not refractory anemia, is the name of the tumor whether the marrow has 8 percent or 80 percent blast cells. The arrest in myeloid development is a major component of pathogenesis, not just ineffective hematopoiesis and dysmorphogenesis.
ETIOLOGY AND PATHOGENESIS
ETIOLOGY
There are, not unexpectedly, close similarities to AML in etiologic factors. Benzene,18,19,20 and 21 chemotherapeutic agents,363,364 particularly alkylating agents and topoisomerase inhibitors,21,22,23,24,25,26,27,28 and 29 and radiation30 are exposures that can increase the risk of these indolent clonal hemopathies. These exposures may cause DNA damage, impair DNA repair enzymes, and induce loss of chromosome integrity. Diseases such as Fanconi anemia, known to predispose to the development of AML, occasionally can evolve instead into a clonal myeloid hemopathy.31,32
Aging is an important factor in the development of clonal myeloid disorders. They increase exponentially in frequency after the age of 40 years.33,34
PATHOGENESIS
These disorders arise from the clonal expansion of a multipotential hematopoietic cell. The clonal origin is supported by studies of women who were heterozygotes for glucose-6-phosphate dehydrogenase isoenzymes A and B and who had such a syndrome. The hematopoietic progenitors35,36 and in some cases lymphocytes37,38 of such patients had only one isoenzyme present, supporting the concept of clonal expansion of a neoplastic marrow cell.39 Clonal studies using X-linked restriction length polymorphisms with probes for hypoxanthine phosphoribosyl transferase or phosphoglycerate kinase also supported the origin of these disorders in a single multipotential stem cell.40,41 and 42
Fluorescent in situ hybridization of interphase blood cell populations with probes for chromosomes 7 or 8 in patients with monosomy 7 or trisomy 8 indicates that chromosome abnormalities may not be present in lymphoid populations.42,43 Studies of immunoglobulin heavy-chain gene rearrangement and assay of the human androgen receptor and other genes on the X chromosome have also concluded that lymphocytes are not derived from the neoplastic clone.44,45 and 46 However, pseudodiploidy has been observed in the Epstein-Barr virus-stimulated cell populations of two patients with idiopathic refractory sideroblastic anemia,47 suggesting that B lymphocytes may be derived from the affected stem cell in some patients.
Molecular genetic studies of patients cells show identifiable gene mutations in about 60 percent. Mutated RAS is most common48,49,50,51,52 and 53; lower frequencies of FMS and p53 mutations are present. Codon 12 of RAS and codon 969 of FMS are the predominant sites of alteration in the respective genes.54,55 Methylation of p15, an inhibitor of cyclin-dependent kinases 4 and 6, was present in over one-third of patients examined.56 A variety of other mutations in protooncogenes, or genes encoding proteins involved in the cell cycle, or of transcription factors have been described sporadically.54,55 Interpretation of these molecular studies is difficult because the mutations are present in advanced disease patients and may be late changes, not seminal in the neoplastic transformation.
The major specific pathophysiologic mechanism in the clonal hemopathies with cytopenias is ineffective hemopoiesis, that is, defective maturation of marrow precursor cells.57 The specific characteristics of ineffective erythropoiesis and granulopoiesis include a decreased proportion of cells in the DNA synthesis phase of the mitotic cycle and a marked increased in the fraction of late precursor cells undergoing apoptosis.58,59 and 60 Increased levels of apoptotic mediators are present in cells including TNF-a, FAS antigen, and calcium-dependent nuclease activity. Characteristic stepwise degradation of DNA is evident in late precursors.61,62 and 63 The proliferation of progenitor and early precursor cells is usually normal or enhanced, resulting in a hypercellular marrow, but there is a failure to accumulate adequate numbers of mature cells. Mild shortening of cell life-span also contributes to the cytopenias.9 As the phenotype of the disease evolves toward myelogenous leukemia, proliferative patterns supersede ineffective hematopoeisis as a result of precursor apoptosis.64 Once the marrow blast percentage is unequivocally above normal (>3 percent) the disease process represents oligoblastic leukemia.
CLINICAL FEATURES
INCIDENCE BY AGE, SEX, AND FAMILIAL OCCURRENCE
The onset of the disease before age 50 years is uncommon except in cases preceded by irradiation or chemotherapy.33,34,65 Myelodysplasia can occur in children aged 5 months to 15 years at a rate of about 0.5 per million,66,67,68 and 69,360 and about half of such cases are oligoblastic leukemia. The incidence increases logarithmically after age 40 years to over 20 per 100,000 in septuagenarians.361 Males are affected about 1.5 to 2.0 times as often as females. Families with an unusually high frequency of clonal myeloid disorders has been described.70,71,362
SYMPTOMS AND SIGNS
Patients can be asymptomatic or, if anemia is more severe, can have pallor, weakness, loss of a sense of well-being, and exertional dyspnea.14,72,73 A small proportion of patients have infections related to granulocytopenia or hemorrhage related to thrombocytopenia at the time of diagnosis, but patients with severe depressions of neutrophil and platelet counts at diagnosis usually have oligoblastic leukemia. Rarely, patients can have fever unrelated to infection.74 Arthralgias are the initial complaint in some patients.75 Very rarely, the presentation may mimic a connective tissue disease.76,77 Hepatomegaly or splenomegaly occurs in about 5 or 10 percent of patients, respectively.
SPECIAL CLINICAL FEATURES
Patients with an indolent phase (smoldering myelogenous leukemia) prior to overt AML may develop diabetes insipidus. Hypothalamic involvement can lead to polyuria, polydipsia, and decreased libido. Hypothalamic-posterior hypophysis insufficiency in clonal myeloid states has been associated with monosomy 7 in hematopoietic cells.78,79 and 80
Acute neutrophilic dermatosis (Sweet disease) is an acute febrile illness with erythematous patches on arms, face, and legs that progress to painful brown plaques that may ulcerate and produce large necrotizing skin lesions. The histopathology of the skin is that of a dense dermal neutrophilic infiltrate.81 This syndrome, which occurs principally in middle-aged women, lasts for 6 to 10 weeks, is often associated with blood neutrophilia, and may recur.82 At least 10 percent of patients with Sweet disease develop AML or another clonal myeloid disease, and occasional cases have been associated with monocytosis or cytogenic abnormalities in marrow cells prior to onset of AML. G-CSF and all-trans retinoic acid (ATRA) administration has been followed by Sweet disease in some cases.83,84 Other dermatopathic conditions also have been associated with clonal myeloid diseases.85
A symptom complex that mimics systemic lupus erythematosus (fever, pleurisy, symmetric arthritis, plasma antinuclear antibody, and pancytopenia with a hyperplastic marrow) may precede AML.76 Several patients with signs of lupus erythematosus (LE) and the LE cell phenomenon have been reported in a review of the clonal hemopathic syndromes.86 Behcet’s disease, glomerulonephritis, seronegative arthritis, and inflammatory bowel disease also have been associated with clonal myeloid disorders.87,88,89 and 90
The incidence of other cancers may be increased in subjects with clonal myeloid disorders.96,97,98 and 99
LABORATORY FEATURES
BLOOD
RED CELLS
Anemia is present in over 85 percent of patients.12,13,14 and 15,72 The mean cell volume (MCV) often is increased.13,14 Red cell shape abnormalities may include oval, elliptical, teardrop, spherical, or fragmented cells. There is a spectrum of red cell findings. Some patients have only slight anisocytosis. Elliptical red cells sometimes dominate. Basophilic stippling of red cells occurs. Nucleated red cells are seen in the blood film in about 10 percent of cases. Reticulocyte counts are usually low for the degree of anemia. Other abnormalities of red cells also occur, such as an increased proportion of hemoglobin F,95 decreased red cell enzyme activities, especially acquired pyruvate kinase deficiency.96 In some cases with pyruvate kinase deficiency, hemolysis has occurred. An enhanced sensitivity of membranes to complement,97 and modification of red cell blood group antigens may be observed.98,99 Acquired hemoglobin H disease results in red cell morphology similar to thalassemia (microcytosis, basophilic stippling, target cells, and teardrop cells). Intracellular precipitates of b-chain tetramers (identified by crystal violet stain) reflect an acquired decrease in the rate of a-chain synthesis in erythroblasts.100,101 The decrease in a-globin chain synthesis is profound, involves each of the four a-chain loci, and results from a transcription abnormality. There are no gross alterations in genes (e.g., insertions, deletions) in these cases.111
GRANULOCYTES AND MONOCYTES
Neutropenia is present in about 50 percent of patients at the time of diagnosis.65 The proportion of monocytes often is increased, and monocytosis per se can be the dominant manifestation of the hematopoietic abnormality for months or years.102,103 and 104 Morphologic abnormalities of neutrophils can occur, sometimes resulting in the acquired Pelger-Huët anomaly. In this condition, the neutrophils have very condensed chromatin and unilobed or bilobed nuclei that often have a pince-nez shape.105 Ring-shaped nuclei also occur in neutrophils.106 Neutrophil alkaline phosphatase activity is decreased in some patients.14 Expression of normal surface antigens on neutrophils and monocytes is decreased, and in some cases abnormal surface antigen expression may occur.107 Defective primary granules of abnormal size and shape with decreased myeloperoxidase content can be present,108 and specific neutrophil granules can be decreased in number, producing hypogranular cells.109 Neutrophil granule membranes frequently are deficient in glycoprotein.110 Chemotactic, phagocytic, and bactericidal capability may be impaired.111,112 and 113 Formyl-leucyl-methionyl-phenylamine receptor signaling and actin polymerization have been abnormal.114,115 Muramidase (lysozyme) activity in blood and urine may be increased, a reflection of granulocytic hyperplasia and heightened monocytopoiesis and monocyte turnover.
PLATELETS
About 25 percent of patients may have mild to moderate thrombocytopenia at the time of diagnosis.14,65 Mild thrombocytosis also can occur.14,65 Platelets may be abnormally large, have poor granulation, or have large, fused central granules.116,117 Abnormal platelet function may contribute to a prolonged bleeding time, easy bruising, or exaggerated bleeding. Decreased platelet aggregation in response to collagen or epinephrine is a frequent functional abnormality.118
LYMPHOCYTES
Patients with clonal hemopathies may have immunologic deficiencies, such as a decrease in natural killer cells in the blood but no decrease in large granular lymphocytes,119,120,121 and 122 a decrease in helper T lymphocytes,120 and a decrease in Epstein-Barr virus receptors on B lymphocytes.120,121,122 and 123 Antibody-dependent cellular cytotoxicity is normal.120 Thymidine incorporation after mitogenic stimulation124,125 and colony growth of T lymphocytes are decreased.138 Lymphocytes may have an increased sensitivity to irradiation.124 The defects in lymphoid cells could reflect the site of the somatic mutation in the pluripotential stem cell in some cases36,37 and 38,40,41 (see “Pathogenesis”).
PLASMA ABNORMALITIES
Serum iron, transferrin, and ferritin levels may be elevated. Lactic dehydrogenase and uric acid concentrations can be increased as a result of ineffective hemopoiesis and a high death fraction of maturing marrow precursors. Monoclonal gammopathy, polyclonal hypergammaglobulinemia, and hypogammaglobulinemia each occur with an increased frequency.126,127 The frequency of autoantibodies was increased in one report127 but not in another.126
MARROW
CELLULARITY
Marrow cellularity is usually normal or increased.128,129 and 130 Occasionally, it may be decreased and may simulate hypoplastic anemia or aplastic anemia,131 although islands of dysmorphic cells are usually present, especially atypical megakaryocytes. An increase in blast cells in this setting suggest hypoplastic myelogenous leukemia (see Chap. 93).
ERYTHROPOIESIS
Erythroid hyperplasia is frequent, and very large or small erythroblasts, nuclear fragmentation, stippled erythroblasts, and poor hemoglobinization may be seen.13,14,132 Proerythroblasts may be in excess, and the marrow may lack normal clusters or islets of erythroblasts. Erythroblasts may resemble megaloblasts that have nuclear-cytoplasmic maturation asynchrony, nuclear fragmentation, or cytoplasmic nuclear remnants. This pattern is referred to as megaloblastoid erythropoiesis.
Pathologic sideroblasts may be identified when the marrow is treated with Prussian blue stain. These include erythroblasts with an increased number and size of siderosomes (cytoplasmic ferritin–containing vacuoles), referred to as intermediate sideroblasts, or erythroblasts with mitochondrial iron aggregates that take the form of a partial or complete circumnuclear ring of iron globules, referred to as ringed sideroblasts. Macrophage iron often is increased. Some observers believe that ringed sideroblasts are associated with progression to leukemia less often than are sideroblasts with increases in cytoplasmic ferritin.133,134 Others dispute this conclusion.135 Ringed sideroblasts, as compared with intermediate sideroblasts, are very uncommon or present only in very low proportions (less than 15 percent) in any clonal myeloid syndrome other than acquired refractory sideroblastic anemia.
GRANULOPOIESIS
Granulocytic hyperplasia is frequent.13,14,128,129 and 130 Marrow monocytes also may be increased in number. Abnormalities of granulocytes include hypogranulation, a monocytoid appearance of neutrophilic granulocytes, and the acquired Pelger-Huët nuclear abnormality of neutrophils. Progranulocytes and myelocytes may be increased. As stated previously, the proportion of blast cells is not increased in clonal hemopathies that are categorized as acquired sideroblastic or nonsideroblastic idiopathic anemia. The latter are syndromes with no increase in blast cells (i.e., less than 2 percent); if the blast percentage is above this level the patient can be considered to have oligoblastic leukemia. Marrow biopsy may show abnormal localized immature precursors (ALIP),135,136 which are clusters of immature myeloid (? blast) cells located centrally rather than subjacent to the endosteum. These clusters of atypical cells are present in virtually all cases of oligoblastic leukemia where blast cells comprise 3 percent or more of nucleated marrow cells (refractory anemia with excess blasts) and in nearly half the patients with refractory anemia, sideroblastic or nonsideroblastic, suggesting that about half these patients have a disorder closely approaching oligoblastic leukemia. Patients with this abnormality are more prone to develop overt AML.135 The number of plasma cells may be slightly increased.
THROMBOPOIESIS
Megakaryocytes are present in normal or increased numbers.13,14,128,129 and 130 Micromegakaryocytes (dwarf megakaryocytes) may occur.128,129 and 130,137,138 Megakaryocytes with unilobed or bilobed nuclei may be increased, and hypersegmented and hyposegmented megakaryocytes may be present. Clusters of megakaryocytes may be seen. Megakaryocytes may be distributed laterally from their usual parasinusoidal location.139
FIBROSIS
An increase in reticulin and collagen fibers of varying degree is common—especially in oligoblastic leukemias. When fibrosis is prominent, the disorder can resemble primary myelofibrosis, although, in contrast to the latter, splenomegaly is usually not marked. Since idiopathic myelofibrosis is an oligoblastic leukemia with striking dysmorphogenesis of cells, some overlap with other fibrotic clonal myeloid disorders is expected.140
The morphologic aberrations (dysmorphogenesis) of blood cells seen in indolent clonal hemopathies can be seen in oligoblastic myelogenous leukemia as well, contributing to the decision to group them together.
CULTURE
The clonal growth of marrow progenitors in soft agar or other viscous culture systems is usually abnormal in patients with clonal hemopathies.141 Most reports indicate that growth of multipotential (CFU-GEMM) and erythroid progenitors (BFU-E, CFU-E) in the blood or marrow is markedly decreased in subjects with clonal myeloid disorders.141,142,143 and 144 Biochemical abnormalities of erythroid precursors have been found also. Colony-forming units for granulocytes and monocytes (CFU-GM) are decreased.140,142 Very small colonies or clusters with impaired maturation often dominate the cultures. Abnormally small and infrequent CFU-GM may be found when blood neutrophil and monocyte counts are nearly normal. Occasionally, overabundant growth is present. Usually, cell culture results become more abnormal as the blood cell abnormalities in the patient worsen.
In overt AML, CFU-GM growth is usually absent. Some studies indicate that very abnormal growth of progenitors in culture (decreased colonies or predominance of small clusters) is a poor prognostic sign and may be a harbinger of overt leukemia.145,146 Growth that does occur in clonal myeloid hemopathies (and AML) usually remains dependent on growth factors such as erythropoietin and granulocyte-macrophage colony-stimulating factor (GM-CSF).147,148 Colony growth in children with the monosomy 7 syndrome may occur without added growth factors supporting the view that there is autocrine and paracrine stimulation of progenitor cells.149,150,151 and 152 Blast cell progenitors (CFU-BL) may be increased in patients with oligoblastic leukemia.150 The long-term marrow initiating cell is decreased in some patients,151,152 and the ability of marrow stromal layers to support in vitro hematopoiesis can be impaired.152
Circulating M-CSF (CSF-1) has been increased in some patients, as well as in AML and other hematologic malignancies, for no clear reason.154 Interleukin-1a (IL-1a) and GM-CSF levels have been undetectable in most patients; IL-6, G-CSF, and erythropoietin concentrations have been variable; and tumor necrosis factor has been inversely related to hematocrit.155 Stem cell factor (SCF), a multilineage hematopoietin, has been decreased in some patients.156 FLT-3 ligand, another multilineage growth factor, is increased in patients with indolent clonal hemopathies but not oligoblastic leukemia.157 The inverse relationship between platelet count and thrombopoietin levels is maintained in acquired idiopathic anemia but not oligoblastic leukemia.158
CYTOGENETICS
An altered number or form of chromosomes may occur in up to 80 percent of patients with clonal hemopathies, depending on the severity of the syndrome.159,160,161,162 and 163 The chromosome abnormalities are nonrandom and often involve chromosomes that are abnormal in patients with AML, although certain chromosomal rearrangements seen in AML such as t(15;17), t(8;21), and inv16 are usually not observed except in oligoblastic leukemias161,162,163 and 164 (see Chap. 10).
Chromosomal abnormalities involving virtually every chromosome have been noted in marrow cells.170,171,172,173,174,175,176,177 and 178,366,367 Common abnormalities include an extra chromosome 8; loss of the long arm of the chromosome 5, 7, 9, 20, or 21; and monosomy for chromosomes 7 and 9. Losses of part or all of chromosomes 5 and 7 and complex chromosome abberations are particularly common in the oligoblastic myelogenous leukemias (and the overt leukemias) associated with prior treatment with cytotoxic drugs, radiation, or exposure to benzene.161,162,163,164,165,166 and 167 The Ph chromosome t(9q+;22q) and numerous other occasional chromosome abnormalities have been described in patients with indolent clonal hemopathies.193,194
The proportion of cases with chromosome abnormalities is different depending on the severity of the clinical manifestations. Chromosome abnormalities are more frequent in patients with refractory anemia with excess blasts (oligoblastic leukemia) than in those with acquired idiopathic anemia. In general, prevalence of chromosome abnormalities and the likelihood of progression to overt AML are both a function of the number of cell lines involved, the severity of the cytopenias, and the proportion of blast cells present.
THE 5Q-SYNDROME
Patients with the 5q-syndrome have refractory anemia and dysmorphic cells in the marrow containing a deletion in the long arm of chromosome 5 (5q-).168,169,170 and 171 The refractory anemia, observed most frequently in older women, is associated with marked dyserythropoiesis, erythroid multinuclearity, and hypolobulated and frequently small (“dwarf”) megakaryocytes. The syndrome can occur in children.171
The critical regions have been mapped to bands 5q31 to 5q33 with the proximal deletion associated with the spontaneous mutation and the distal region with the posttherapy-related event.169,170 and 171 The genes that encode for the multipotential growth factor IL-3168; for the bipotential growth factor for granulocytes and monocytes, GM-CSF172; and IL-4, -5, and -9 are located on the portion of chromosome 5 that is deleted in the 5q-syndrome. Gene mapping studies indicate that the IL-3/GM-CSF and IL-4/IL-5 gene clusters are proximal to and excluded from the rearranged region (5q31) associated with myeloid leukemias.173 The monocyte colony-stimulating factor, M-CSF (CSF-1) gene, previously thought to be on chromosome 5, has been relocated to chromosome 1174 but the FMS gene, encoding the receptor for M-CSF (CSF-1), is on the long arm of chromosome 5 in the region deleted in the 5q-syndrome.175,176 The genes for three additional growth factors, IL-1, platelet-derived growth factor, and endothelial cell growth factor, are also on chromosome 5168 but not on the segment deleted in the 5q-syndrome. The pathogenetic role of the genes deleted in this syndrome is not known, since only a single allele is involved, and unaffected cells (e.g., T lymphocytes, fibroblasts, endothelial cells) also may produce identical growth factors.
A number of other growth-related genes such as the EGR, CDC25C, and interferon regulatory genes also are located on 5q.168,177,178,179 and 180 A tumor suppressor gene might be located at 5q31, the smallest commonly deleted segment in 5q-syndrome. The interferon regulatory factor-1 (IRF-1) gene, encoding a DNA-binding protein that binds to a promoter element for IFN-a, IFN-b, and other IFN-inducible genes, also has been localized to 5q31. Rearrangements of this gene have been found in some patients with oligoblastic and overt myelogenous leukemia and 5q-.177,178,179,180 and 181 The action of IRF-1 is antagonized by IRF-2, and imbalanced expression of IRF-1 relative to that of IRF-2 activity could predispose to neoplastic transformation. The associated proximal break points at 5q12 to 15, sometimes seen in the relatively benign 5q-syndrome, may be associated with preservation of granulocyte and platelet counts and reduced infection and bleeding complications. Patients with this disorder have a risk of developing AML that is similar (about 15 percent) to that of patients with refractory anemia and marrow cells without 5q-.
MONOSOMY 7 SYNDROME
Monosomy 7 is the second most frequent cytogenetic abnormality in the marrow cells of patients with myelodysplasia. It often occurs in marrow cells of subjects exposed to chemicals or radiation and is associated with a poor prognosis and rapid transformation to AML.184,185 A critical region may reside in bands 7q35–36.186 Monosomy 7 syndromes, aside from being difficult to classify, usually are not associated with special clinical features in adults, although in children they are characterized by an atypical myeloproliferative disorder or myelomonocytic leukemia with abnormal expression of the neurofibromatosis (NF1) and Wilm’s tumor (WT1) genes, unusual susceptibility to infection, and a rapid termination in acute leukemia66,184,185,186 and 187 (see Chap. 93). Monosomy 7 also occurs in a familial form and during leukemic evolution of Down syndrome and Fanconi anemia.188,189 A variant of the monosomy 7 syndrome, translocation 1;7, also is seen in adults and children and may be preceded by exposure to cytotoxic treatment.190,191 The ERB-B gene, which encodes a shortened form of the epidermal growth factor receptor, is amplified in this syndrome.192
SPECIFIC CLONAL MYELOID SYNDROMES
These syndromes highlight the variability in expression of the clonal hemopathies (Table 92-1). Most patients have one of the syndromes described below.

TABLE 92-1 PRODROMAL AND OLIGOBLASTIC (LOW-INFILTRATE) MYELOGENOUS LEUKEMIA

ACQUIRED IDIOPATHIC SIDEROBLASTIC ANEMIA
HISTORY
The term refractory anemia has been used to define erythropoietic insufficiencies that cannot be assigned to a specific vitamin or mineral deficiency and thus are unresponsive to the known hematinics. In 1956, Bjorkman defined a subset of refractory anemias by the presence of ringed sideroblasts in the marrow.195 The intramitochondrial location of the iron in the ringed sideroblasts was described a year later.196
PATHOGENESIS
The disorder is a multipotential stem cell defect in which ineffective erythropoiesis with normal or slightly shortened red cell survival and only slight impairment of the maturation of other cell lineages occurs.197,198,199 and 200 The plasma iron turnover is increased, but incorporation of radioactive iron into heme and its delivery to blood as newly synthesized hemoglobin are depressed.197 Impairment of heme biosynthesis results in mitochondrial iron overload, which may inhibit mitochondrial function and contribute to the premature destruction of marrow erythroid precursors.200 Missense mutations in the gene encoding delta-aminolevulinate synthetase,201 or in a mitochondrial transfer RNA,202 and in red cell 5-aminolevulinic acid synthetase (205C) have been described, but a common gene alteration has not been correlated with this disease.
CLINICAL FEATURES
The disease is very uncommon under age 5033,203,204 and 205 except in patients in whom it occurs as a result of radiotherapy or chemotherapy of a malignant tumor.206 Males and females are affected almost equally. A rare concurrence of familial sideroblastic anemia has been reported.207 The signs and symptoms are those of anemia: pallor, easy fatigue, weakness, and dyspnea and palpitations on exertion.199,204 Most patients have the anemia detected as a result of blood cell analysis for other medical reasons. The liver may be slightly enlarged. The spleen is slightly increased in size in about 5 percent of patients. Splenic and hepatic enlargement do not necessarily occur together, and more than slight enlargement is unusual.
LABORATORY FEATURES
Most patients have mild to severe macrocytic anemia.199,204 The blood film often contains a population of hypochromic cells (dimorphic red cell changes).198,199,204,205 Red cell anisocytosis, basophilic stippling, and slight poikilocytosis may be present. The total white cell count and platelet count are usually normal, but mild abnormalities may be seen, including a decreased white cell count and an increased or decreased platelet count. Occasionally, the white cell count or platelet count may be increased markedly, or nucleated red cells may be present in the blood film. The reticulocyte percentage is usually between 0.5 and 2.0. Hemoglobin F concentration may be increased slightly.
Marrow cellularity usually is increased as a result of erythroid hyperplasia. Evidence of dyserythropoiesis in the form of vacuolated, small, large, or binucleate erythroblasts may be present. Prussian blue stain of the marrow invariably shows pathological sideroblasts. The latter may have Prussian blue–positive cytoplasmic granules in a partial or complete circumnuclear pattern (ringed sideroblasts) in 15 percent or more of cells or an increased number (more than 5) of Prussian blue–positive granules in their cytoplasm. If the disease progresses to oligoblastic leukemia, sideroblasts may become less prominent.208 Granulopoiesis and thrombopoiesis are not altered significantly in two-thirds of patients.205 In the other third, dysgranulopoiesis (hypogranulation, acquired Pelger-Huët anomaly, hypersegmented nuclei, or granule abnormalities) or dysmegakaryocytopoiesis (micromegakaryocytes, large lobulated cells) may be present. Marrow iron stores are increased often.
Cytogenetic abnormalities in marrow cells of patients with acquired refractory sideroblastic anemia provide evidence for the clonal character of the disease. About half of the reported cases with sideroblastic anemia in which cytogenetic studies have been performed have a chromosomal abnormality.204 Involvement of chromosomes 8, 11, and 20 has been notable159,160,161 and 162,209,210 and 211; the Philadelphia chromosome has been reported212; involvement of chromosome 3 has been associated with thrombocytosis.213 The absence of the Y chromosome, only in the pathological sideroblasts in one report (45;X/46;XY mosaic), substantiates the dimorphic nature of the erythroid lineage involvement and parallels the hypochromic and normochromic red cell populations.214 Involvement of the X chromosome (a breakpoint at Xq13) of female patients with sideroblastic anemia215,216 is of note because a type of hereditary sideroblastic anemia is X chromosome–linked (see Chap. 63).
Serum iron levels and saturation of transferrin are increased. Serum ferritin concentration is increased, reflecting an increase in body iron stores. Bilirubin-proteinate levels (indirect-reacting fraction) may be increased as a result of ineffective erythropoiesis and intramedullary hemolysis.
DIFFERENTIAL DIAGNOSIS
The principal considerations are those anemias with an inadequate reticulocyte response in which erythrocytes are hypochromic. Iron deficiency anemia in contradistinction to sideroblastic anemia is associated with low serum iron levels, saturation of transferrin of less than 16 percent, low serum ferritin concentration, elevated serum transferrin receptors, and absent marrow sideroblasts and macrophage iron. Beta thalassemia minor is characterized by normal to elevated serum iron and ferritin, a low mean red cell volume, elevated hemoglobin A2 concentration, and evidence of the disease in a parent, siblings, or offsprings. Detection of secondary forms of sideroblastic anemia requires evaluation for exposure to lead or other agents or diseases listed in Chap. 63, as do the hereditary sideroblastic anemias.
THERAPY
Some patients do not require treatment, since the moderate decrease in hemoglobin concentration is tolerated without limitation of usual activities. Occasional patients who have low serum and red cell folate concentrations may have partial improvement in blood hemoglobin concentration after the administration of folic acid (1 mg/day, orally). Rare patients may benefit temporarily from pharmacological doses of pyridoxine (200 mg/day, orally for at least 3 months) or danazol.217 A therapeutic trial with folic acid and pyridoxine is worthwhile if the anemia is symptomatic, even though only a small percentage of patients are responsive. If anemia is severe or symptoms of heart failure or coronary insufficiency are present, periodic transfusion of red cells is required. Recombinant human erythropoietin generally is not useful unless the pretreatment serum erythropoietin level is below 200 milliunits per ml, an infrequent finding in these patients.218 The combination of G-CSF with erythropoietin may increase the response rate to over 40 percent.219 Erythropoietin, 20,000 to 40,000 units subcutaneously, once a week coupled with G-CSF, 300 µg subcutaneously, two or three times per week, is one regimen that can be used if the cytopenias are not tolerated.
COURSE AND PROGNOSIS
In many patients the disorder lasts for years without progression of the anemia or symptoms. A small proportion of patients may have progressive marrow failure, severe cytopenia, and morbidity from infections or hemorrhage. Iron overload is common, and some patients may develop hemochromatosis.220 The frequency of HLA-A3 is significantly higher in patients who develop iron overload than in the general population. The frequency is comparable to that found in hereditary hemochromatosis,221 suggesting that the combination of a genetic predisposition plus sideroblastic anemia facilitates the expression of iron overload in these patients. Evidence in support of this linkage has not been found after search for mutations associated with hemochromatosis.222 The appearance of hemochromatosis may be accelerated if frequent transfusions have been required for a period of years.220 Improvement of the anemia and the adverse effects of iron overload in parenchymal tissues can occur following cautious phlebotomy or chelation therapy.223,224 and 225
Over a 10- to 15-year period about 10 percent of patients with acquired refractory sideroblastic anemia will develop AML.220,226,227,228 and 229 The progression to leukemia is correlated with the degree of dyshematopoiesis and trilineage abnormalities.208 Transformation to acute lymphocytic leukemia also has occurred.230 In one series of 37 patients, 25 had abnormalities confined to the erythroid series, transfusion dependence occurred in 26, and iron overload was common. Five patients progressed to marrow failure and five to AML. Median survival was 72 months.231 Survival in other series has ranged from 21 to over 60 months.72 Survival is better in patients without abnormalities in lineages other than erythroid cells and with favorable cytogenetic findings.232 This also applies to acquired refractory nonsideroblastic anemias and oligoblastic leukemia233 (see below).
ACQUIRED IDIOPATHIC NONSIDEROBLASTIC ANEMIA
This clonal disorder closely mimics sideroblastic anemia and can occur without prominent sideroblasts in the marrow. The anemia is mild to moderate, with a tendency to macrocytosis. Leukopenia and thrombocytopenia, if present, are usually mild.205,234 Hyposegmented and hypersegmented neutrophils, giant platelets, and red cell shape, size, and hemoglobinization abnormalities may be present. The marrow is usually cellular, and the precursors may show morphologic evidence of dyshemopoiesis, especially in the erythroid series, but ringed sideroblasts are absent or, in one classification scheme, less than 15 percent of erythroid cells. Since anemia predominates and other cytopenias are slight, the course and management are similar to that of acquired idiopathic sideroblastic anemia with dysmorphogenesis, principally. Patients with low erythropoietin levels may have a significant increase in hemoglobin concentration with weekly injections of the hormone. The proportion of patients transforming into AML and the median survival of patients are similar to patients with acquired idiopathic sideroblastic anemia, particularly cases with accompanying disturbances in granulopoiesis or megakaryopoiesis.232,235,236 Cytopenias and blood and marrow dysmorphic changes can become more severe, and the course and management in that instance are similar to multilineal cytopenia with hypercellular marrow, discussed below.
MULTILINEAL CYTOPENIA WITH HYPERCELLULAR MARROW
Approximately two-thirds of patients with clonal myeloid hemopathy present with neutropenia and/or thrombocytopenia in addition to anemia.
CLINICAL FINDINGS
These patients present with anemia, neutropenia, and thrombocytopenia; anemia and neutropenia; or anemia and thrombocytopenia. The blood and marrow features are as described above in “Laboratory Features” and lead to a diagnosis, especially in the patient over 50 years of age.9,10,11,12,13,14,15 and 16,237,238 The patient usually seeks medical attention for symptoms of anemia: fatigue, dyspnea, and palpitations on exertion, headache, or dizziness. Exaggerated bleeding associated with thrombocytopenia also may be present. Mild hepatomegaly and/or splenomegaly may be present occasionally.
Dysmorphic blood and marrow cell changes are common. Myeloblasts are not increased in the marrow (less than 2 percent) and are absent from the blood. Cytogenetic abnormalities may be present as described under “Cytogenetics.” If monocytosis is greater than 1000/µl (1000% 106/liter), the disorder merges with chronic myelomonocytic leukemia149(see Chap. 94).
DIFFERENTIAL DIAGNOSIS
Mild to moderate bicytopenia (anemia and neutropenia) and sometimes tricytopenia with dysmorphic blood and marrow findings and hypercellular marrow occur in patients with the acquired immune deficiency syndrome239,240 but have not been associated with progression to acute leukemia. Pancytopenia with hyperplastic marrow has been associated with nonhemopoietic cancers (paraneoplastic syndrome).241 Megaloblastic anemia can be simulated and can be distinguished by the normal concentration of serum or red cell folate and of serum vitamin B12.
TREATMENT
In patients with pancytopenia and hyperplastic marrow, cytopenias that are not troublesome should not be treated. Transfusion of blood components when necessary is the mainstay of treatment. Regular transfusion of red cells may be used for those who do not adapt to moderate anemia or in whom medical conditions, such as angina pectoris, require a higher packed red cell volume. Erythropoietin with or without G-CSF administration may increase hemoglobin concentration and decrease transfusion frequency. Thrombocytopenia is often not so severe as to require treatment. If thrombocytopenic bleeding occurs, platelet transfusions should be used. Amincaproic acid (Amicar) may be a useful adjunct to platelet transfusion for thrombocytopenic bleeding. Interleukin 11 may increase platelet counts in some patients. Stem cell factor, interleukin 3, or thrombopoietin are not approved for clinical use at this time. Amifostin, an aminothiol agent used for radioprotection, given in doses of 100 to 200 mg/m2 three times a week may increase blood counts in some patients.242 Asymptomatic neutropenia should not be treated, but fever should be evaluated promptly and suspected infection treated with broad-spectrum bactericidal antibiotics until the results of cultures are known. In appropriate situations oral antibiotics can be used in patients treated at home.243,244
Androgens have not been generally useful. Rare cases may show minor improvement, but the likelihood of substantial or sustained improvement is low. Occasional cases have shown improvement in blood cell counts and, where present, resolution of myelofibrosis following use of glucocorticoids (prednisone, 40 mg/m2 per day, orally245 or prednisone, 60 mg qd).246 Protracted use of glucocorticoids may increase the risk of infection, especially with opportunistic organisms, and has not been shown to increase survival.
For those patients with symptomatic anemia and high transfusion requirements or severe, symptomatic neutropenia, therapeutic trials of erythropoietin247,248,249 and 250 and/or GM-CSF, G-CSF,251,252,253,254 and 255 or IL-3256 have sometimes been beneficial in increasing counts and improving neutrophil function. Cytokines have not been shown to increase survival and can produce troubling side effects such as local skin reactions, fever, bone pain, and a capillary leak syndrome.247,257 They also can lead to an increase of immature granulocytes including blasts to increase in marrow and blood.258
In uncommon cases with hypoplastic marrows, cyclosporin A and antithymocyte globulin have been used,259,260 analogous to the responsiveness of some cases of aplastic anemia to such approaches. A variety of chemotherapeutic agents have been used, especially when the disease evolves to oligoblastic or frank AML (see oligoblastic leukemia, “Treatment”).
COURSE AND PROGNOSIS
In patients with multicytopenias, morbidity is great; severe infections, exaggerated bleeding, and severe anemia and lassitude may occur. Mortality from infection or hemorrhage occurs in about 25 percent of patients. AML develops in about 50 percent of patients. There is a greater likelihood of transformation to overt AML if the patient has severe cytopenias, more overt qualitative disorders of cells, abnormal localized immature myeloid precursors in marrow, complex chromosome abnormalities, and abnormalities of marrow cell colony growth in culture (excessive growth or decreased growth).233,261,262 Median survival of patients with clonal hemopathy and multicytopenias is about 20 months.
UNCOMMON PRELEUKEMIC SYNDROMES
ISOLATED THROMBOCYTOPENIA
Amegakaryocytic thrombocytopenia is a very uncommon preleukemic syndrome (less than 1 percent), although bonafide cases have transformed into AML months or years later.263,264 Among 1220 cases of myelodysplastic syndrome, 11 cases of isolated thrombocytopenia associated with clonal chromosome abnormalities, usually involving chromosomes 3, 5, 8, or 20, were identified. Antiplatelet antibodies were not present, and glucocorticoids were ineffective. Five of the 11 patients progressed to acute myelogenous leukemia.263 (See Table 92-2.)

TABLE 92-2 HYPOCELLULAR MARROW SYNDROMES THAT OCCASSIONALLY PRECEDE ONSET OF ACUTE MYELOGENOUS LEUKEMIA

ISOLATED NEUTROPENIA
Chronic neutropenic states are rare antecedents of AML.265 Congenital neutropenia (Kostmann syndrome) has evolved into AML.265,266 The evolution of Shwachman syndrome (neutropenia and exocrine pancreatic insufficiency) into oligoblastic or overt acute leukemia has been documented.267 A related disorder, Pearson syndrome (sideroblastic anemia, neutropenia, and exocrine pancreatic insufficiency), is a putative preleukemia disorder in children268 (see Chap. 31).
MONOCYTOSIS
In a small proportion of patients with preleukemia, monocytosis may be the most striking blood cell abnormality for months or years before the development of acute leukemia.102,103 and 104
APLASTIC ANEMIA, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, AND EOSINOPHILIC FASCIITIS
AML occurs in a small fraction of patients (approximately 5 percent) with acquired aplastic anemia.269,270 Since aplasia itself is a disease with a high early mortality rate, the propensity to leukemia may be greater than is apparent. Patients initially responding to glucocorticoids or antithymocyte globulin have later developed myelodysplastic syndromes.270
Paroxysmal nocturnal hemoglobinuria is a hemopoietic stem cell disease that often is associated with marrow hypoplasia (see Chap. 36). AML may ensue in some patients.97 It is a preleukemic syndrome with a very low incidence of leukemic transformation. There is a propensity for all chronic hemopoietic stem cell disorders (e.g., polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis, chronic myelogenous leukemia) to undergo transformation to AML (see Chap 91). Patients with indolent myeloid clonal disorders may have a PNH-like defect of their blood cell membranes.27
Eosinophilic fasciitis mimics the cutaneous manifestations of scleroderma. Symmetrical swelling and induration of arms and legs, sparing the hands and feet, are common.272,273 Eosinophilia and hypergammaglobulinemia are frequent, and immune cytopenias, aplastic anemia, myelodysplasia, AML, and lymphoma has been associated with the disease.274 An immune mechanism has been postulated for all the manifestations of the disease. The risk of developing AML is greatly increased compared with healthy individuals.272,273 and 274 Marrow transplantation has been used to treat the aplastic anemia.275
OLIGOBLASTIC LEUKEMIAS
DEFINITION AND HISTORY
In 1963, the term smoldering acute leukemia was introduced to highlight a subset of patients, usually those over 50 years of age, who had a low proportion of leukemic blast cells in marrow (5 to 30 percent) and blood (0 to 10 percent) and who survived for months or years without specific therapy for leukemia.276,277 and 278 Oligoblastic leukemia has been called refractory anemia with excess myeloblasts, and when the blast count increases further the phrase in transformation had been added.2 The latter distinction has proved of little value and has been abandoned. Chronic myelomonocytic leukemia, previously included under the rubric myelodysplasia, is better linked to the subacute and chronic myelogenous leukemias discussed in Chap. 94. Happily this change further minimizes the oxymoronic classification that considers leukemia a dysplasia.
OLIGOBLASTIC LEUKEMIA (REFRACTORY ANEMIA WITH EXCESS MYELOBLASTS)
This disorder is referred to by the acronym RAEM (or RAEB, refractory anemia with excess blasts).2,279,280 Most patients are over 50 years of age. Males and females are affected about equally. Reticulocytopenic anemia, granulocytopenia, and/or thrombocytopenia are present. Qualitative abnormalities of blood cells may develop as described above under “Laboratory Features.” Myeloblasts and progranulocytes constitute from 3 to 30 percent of nucleated marrow cells. Some subclassify this group into RAEB (20 percent or fewer marrow blasts). (RAEB in transformation had been used in those cases with 20 to 30 percent marrow blasts but has been dropped.) Auer rods may be present in blast cells. Dysmorphic changes that may occur in marrow precursor cells are described above in “Laboratory Features.” This syndrome evolves into overt AML in about 30 to 50 percent of cases.281 Median survival in RAEB is about 9 months, although there are occasional long-term survivors.
TREATMENT, COURSE, AND PROGNOSIS
The treatment of oligoblastic leukemia should be highly individualized. In some cases no active treatment is required. Periodic evaluation is essential to detect deterioration in well-being or blood cell counts. Most patients will require treatment in weeks to months. The response to cytotoxic therapy is poor, and symptomatic therapy with component transfusion and antibiotics, as required, is the preferable management if that approach can sustain a reasonable functional status. If the disease progresses to frank AML and if the patient is fit, standard therapy as for AML is warranted (see Chap. 93). If the patient is over 70 years, attenuation of doses should be considered. Cytarabine combined with anthracycline antibiotics, etoposide, or topotecan have produced remissions in about half of a group of selected patients.282,283,284,285,286,287,288 and 289,370 Recovery may be slow, and remissions tend to be short, however. Patients with a poor performance status, in advanced age, or choosing not to be treated with combined-agent chemotherapy have been treated with low-dose cytarabine, 5-azacytidine or decitabine, etoposide, hydroxyurea, retinoids, butyrates, or interferon coupled with transfusion therapy for palliation of the disease (see below). Although occasional patients have improvement, these approaches have been of limited benefit. Patients under 50 years of age with a histocompatible donor should be considered for stem cell transplantation.290,291 and 292 Other patients including older individuals who achieve a remission may be considered for intensive therapy and autologous stem cell rescue.293
LOW-DOSE CYTARABINE
Chemotherapeutic regimens containing standard doses of cytarabine and daunomycin (see Chap. 93) result in remission in fewer than 20 percent of patients with oligoblastic leukemia. Moreover, a proportion of patients are made worse with intensive chemotherapy. The advanced age and the high frequency of cardiac, renal, immunologic, and other organ system impairment in most patients with oligoblastic leukemia are largely responsible for the poor outcome. Patients who are less than 50 years of age have higher remission rates and should undergo intensive therapy. However, such cases represent only about 10 percent of all patients.
Low-dose cytarabine, 5 to 20 mg/m2 per day by subcutaneous injection every 12 h for up to 8 to 16 weeks or by continuous intravenous infusion, has been used in lieu of intensive chemotherapy.294,295 Although this approach has led to remission in about 20 percent of patients with oligoblastic leukemia, the median duration of remission is only about 10 months, and survival has not been prolonged when compared with supportive care alone. Also, in contrast to AML, survival has not been influenced greatly by induction of a remission. Moreover, low-dose cytosine arabinoside is usually cytotoxic, inducing marrow hypoplasia and worsening cytopenias. Often the patient requires hospitalization and blood cell component transfusion and antibiotic treatment analogous to that used for intensive treatment of AML. In some cases, outpatient therapy is possible with self-administration of subcutaneous cytarabine. Although occasional reports of remission following low-dose cytarabine have been consistent with an effect on leukemia cell maturation, most patients experience suppression of the malignant stem cell clone leading to marrow repopulation with polyclonal hemopoiesis.289,294,295 Combinations of low-dose cytarabine with growth factors have not shown a clear advantage over chemotherapy alone.295
5-AZACYTIDINE
This agent is a pyrimidine analogue that inhibits DNA methyltransferase, reduces cytosine methylation, and induces maturation of some leukemic cell lines. It also is an antiproliferative drug. Administration of the drug and its congener, decitabine, has resulted in improvement of some pateients with oligoblastic leukemia.287,288 5-azacytidine in a dose of 75 mg/m2 once per day given subcutaneously for 7 consecutive days each month provided significantly more frequent benefit to two-thirds of the patients than did supportive care. Quality of life was enhanced, and disease progression was delayed.288 The drug is available from the National Cancer Institute on the basis of “compassionate use.”
OTHER CYTOTOXIC DRUGS
Agents such as hydroxyurea and low-dose etoposide are useful in controlling leukemic cell proliferation but usually produce only partial responses and do not influence survival duration.296 Occasional patients have achieved remissions with etoposide (50 mg as a 2-h infusion, two to seven times weekly for 4 weeks; or 100 mg per day, orally, for 3 days and then 50 mg twice weekly).297 Thalidomide has shown effectiveness in early pilot studies. Further trials alone and in combination with other agents are in progress.369
RETINOIDS, VITAMIN D DERIVATIVES, OTHER POTENTIALLY MATURATION-ENHANCING AGENTS
Glucocorticoids, vitamin A analogues (retinoids), vitamin D analogues (dihydroxyvitamin D3), pyrimidine analogues (cytarabine), hexamethylene bisacetamide, and interferons among other agents can induce in vitro maturation of mouse and human leukemic cells.298,299,300 and 301 The use of 20 to 100 mg/m2 of cis-retinoic acid, 25 mg/m2 of isotretinoin, or 45 mg/m2 of all-trans retinoic acid, orally, daily for up to 3 months has produced only slight, transient (few weeks) improvement in a very small proportion of patients with oligoblastic leukemia.302,303 Adverse effects of these vitamin A derivatives include dry skin, cheilitis, pruritus, lethargy, and arthralgia, which usually disappear after discontinuation of the agent.
A regimen including 2.5 µg per day, orally, of dihydroxyvitamin D3 for at least 8 weeks has not been beneficial in patients with oligoblastic leukemia.304,305 Hypercalcemia has been a dose-limiting factor. Analogues with less hypercalcemia-inducing capacity such as alphacalcidol have shown some effect on reducing blasts and promoting monocytoid differentiation, while others have been inactive.306,307
A combination of low-dose cytarabine, retinoic acid, and 1,25-dihydroxyvitamin D3 in 44 patients with oligoblastic leukemias produced 50 percent response rates, with longer survival in responders than in nonresponders.308 Hexamethylene bisacetamide given in a dosage of 20 to 24 g/m2 per day intravenously for 10 days followed by an 18- to 75-day observation period produced increased neutrophil counts and reduced marrow blasts in only 4 of 16 patients with oligoblastic leukemia.301 In another study no responses were observed.299 Sodium phenylbutarate is an agent that has shown some activity against oligoblastic leukemia and is in early clinical trials.300
Amifostine, pentoxifylline, and dexamethasone has shown effectiveness in prolonging survival of patients. The combination is thought to reverse the exaggerated apoptosis of maturing precursor cells.368
INTERFERONS
Interferons also have been used to treat oligoblastic leukemia.309,310,311 and 312 Doses of IFN-a ranged from 3 × 106 units per day to 1 × 106 units/m2 three times a week. Occasional reductions in blast percentages or transfusion requirements have occurred at the price of substantial toxicity. AML occurred in some patients. IFN-g at 0.01 mg to 0.1 mg/m2 three times weekly improved counts and reduced blast percentages in about 40 percent of 30 patients with oligoblastic leukemia in one series. Median survivals were no longer than in untreated historical controls, although they were longer than in untreated concurrent patients. Other reports show little effect from interferon treatment.313,314
INTERLEUKIN-2
In one case of therapy-related oligoblastic leukemia developing during a third complete remission of ALL, IL-2 given subcutaneously at 2.5 to 8 × 105 IU twice daily for 30 days enhanced natural killer cell activity and eliminated blasts in the marrow.315 A phase II clinical trial, however, failed to show improvement in blood counts or decrease in transfusion requirement in patients so treated.316
ERYTHROPOIETIN, GM-CSF, G-CSF, IL-3, AND IL-11
Randomized, double-blind studies have not shown that any cytokine prolongs survival or reduces morbidity in oligoblastic leukemia, although the results of early studies suggest that (1) erythropoietin occasionally can reduce transfusion requirement, (2) GM-CSF and G-CSF can increase neutrophil counts and functions, and (3) IL-3 can result in increased white cell count and, less frequently, increased red cell and platelet counts.248,249 and 250,317,318,371 Responses have been seen in oligoblastic leukemias as well as in severe refractory anemias. There is no evidence that cytokines can delay emergence of acute leukemia; rather, they increase blast percentages in a proportion of patients, an event that is not always reversible with cessation of the cytokine.317,318 In one review, 22 of 83 reported cases of myelodysplasia treated with G-CSF or GM-CSF had an increase in marrow blast percentage, and AML developed in 12 of 69 patients. An increased percentage of abnormal macrophages has also been reported.319 Use of these agents without chemotherapeutics in oligoblastic leukemias carries a risk of accelerating the leukemia.320 Combinations of growth factors alone or coupled with maturing agents have not significantly improved response or survival rates.321,322 IL-11 is being studied as a means of increasing the platelet count in patients with myelodysplasia and symptomatic thrombocytopenia.373
STEM CELL TRANSPLANTATION
ALLOGENEIC STEM TRANSPLANTATION
This approach has been used to treat various myelodysplastic syndromes in patients from 1 month to 60 years of age.323,324,325,326,327,328 and 329,372 Conditioning regimens have been cyclophosphamide plus irradiation or busulfan plus cyclophosphamide. Most patients have received transplants from histocompatible sibling donors, although there is some experience with partially mismatched, related, and unrelated donors. A good representation of the results of this approach using marrow stem cells is the study of 93 patients ranging in age from 1 month to over 60 years (median of 30 years), conditioned with cyclophosphamide and total body irradiation or busulfan and cyclophosphamide, and transplanted with an identical twin donor (3 patients), genotypically HLA-identical sibling (62 patients), HLA-matched family member (2 patients), one to three antigen HLA-mismatched family member (20 patients), or unrelated donor marrow (6 patients). Twenty-nine patients were in the refractory anemia category. Forty-seven recipients were in the oligoblastic leukemia category, and the remainder comprised miscellaneous disorders. Most patients received graft-versus-host disease prophylaxis with methotrexate and cyclosporine, with or without prednisone. The most favorable results were in patients less than age 40 years with shorter duration of disease and without blasts. These patients may have a disease-free survival of 60 percent at 4 years and an overall disease-free survival estimated at 40 percent. Older patients had more peritransplant mortality and higher relapse rates. Actuarial relapse probability at 4 years was 30 percent for the entire group and 50 percent for patients with greater than 5 percent marrow blasts. Cytogenetic abnormalities did not predict outcome in this study, but adverse cytogenetics were an important prognostic factor in other studies. Results with unrelated marrow donors are inferior to those for other donor categories.
AUTOLOGOUS STEM CELL INFUSION
Patients with oligoblastic leukemia have been treated with their own stem cells following intensive chemotherapy therapy.330 The approach is limited by the contamination of the stem cell product with leukemic cells and the absence of a graft-versus-leukemia effect. The absence of a graft-versus-host reaction makes it more applicable to the age group usuially affected. In selected patients, peritransplant mortality with intensive therapy and stem cell rescue has been about 10 percent, and about 50 percent of selected patients have had extended survivals.331 The more advanced the disease at the time of treatment the worse the outcome.
COURSE AND PROGNOSIS
The median survival in published series of patients with oligoblastic leukemia has varied from 6 to 36 months, with a range of survival of individual patients from 1 to 160 months.332,333,334,335 and 336 In a very large single series that included refractory anemia as well, the median survival was 15 months.278 About half the patients died of infection associated with severe neutropenia or with dysfunctional neutrophils and monocytes, and about 25 percent died of bleeding complications of thrombocytopenia. About 30 percent of cases evolved into AML. The length of survival after diagnosis of patients with oligoblastic leukemia is inversely correlated with the severity of the cytogenetic abnormality, the proportion of blast cells in the marrow, the presence of N-RAS mutations, the presence of adverse cytogenetic patterns, and the severity of the neutropenia and thrombocytopenia.332,333,334,335 and 336,374,375
A rare case of spontaneous disappearance of oligoblastic leukemia has been documented.337
PRODROMAL SYNDROMES ANTEDATING LYMPHOCYTIC LEUKEMIA
The indolent clonal disorder usually implies a condition that is an antecedent of myelogenous leukemia. AML often begins with a protracted period (weeks to months) of symptoms or signs preceding clinical diagnosis, and a significant proportion of cases are preceded by a myelodysplastic syndrome. Acute lymphocytic leukemia (ALL) usually begins explosively, and it is rare for symptoms to be present for more than a few weeks prior to diagnosis (see Chap. 97). Intermediate syndromes, for example, smoldering or oligoblastic lymphocytic leukemia or prodromal clonal anemias, are rare, but the latter have been reported, especially in adults.338,339,340,341 and 342,376
Apparent aplastic anemia343,344,345,346 and 347 or erythroid hypoplasia348 has been described as an antecedent to ALL in a few children and a rare adult.348 The aplasia is promptly improved by glucocorticoids, and ALL ensues quickly, usually within 1 to 8 months. The brief interval between remission of aplastic anemia and the onset of leukemia suggests that the leukemia, although inapparent on marrow biopsy, may in some way initiate the aplasia.347 Remission of aplasia followed shortly by ALL has occurred in the absence of glucocorticoid or other specific therapy in several cases. The aplastic marrow prodrome of ALL may be distinguishable by its very high prevalence in females (about 90 percent), high prevalence of fibrosis on marrow biopsy (about 90 percent), frequent marrow lymphocytosis (about 60 percent), and spontaneous, temporary recovery (greater than 90 percent).349
INDOLENT CLONAL MYELOID DISORDERS OR OLIGOBLASTIC (MYELOGENOUS) LEUKEMIA PRECEDING OR EMERGING IN LYMPHOID MALIGNANCIES OTHER THAN ACUTE LYMPHOCYTIC LEUKEMIA
Sideroblastic anemia sometimes associated with qualitative disorders of other blood cell lines (such as thrombopathy) has developed in patients who have had, or later developed, a lymphoproliferative disease such as hairy-cell leukemia, lymphocytic lymphoma, myeloma, chronic lymphocytic leukemia, or Hodgkin’s disease.350,351,352,353,354,355,356,357,358 and 359 The sideroblastic anemia in these cases was not preceded by cytotoxic therapy. Similar associations have been reported in patients who have received chemotherapy or radiotherapy for a lymphoproliferative disease or a solid tumor, and who later developed a preleukemic syndrome presumed to be the result of the prior treatment. Other types of myelodysplasia also can occur concurrent with B- or T-lymphocyte–derived tumors.350,351,352,353,354,355,356,357,358 and 359
CHAPTER REFERENCES

1.
Heaney ML, Golde DW: Myelodysplasia. N Engl J Med 340:1649, 1999.

2.
Bennect JM, Catovsky MT, Daniel, MT et al: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:184, 1982.

3.
Layton DM, Mufti GJ: Myelodysplastic syndromes: their history, evolution, and relation to acute myeloid leukemia. Blut 53:423, 1986.

4.
Dreyfus B, Rochant H, Sultan C, et al: Les anémies refractaires avec excès de myeloblastes dans la moelle. Etude de onze observations. La Presse Med 78:359, 1970.

5.
Chevallier P: Sur la terminologie des leucoses et des affection frontieres. Le Sang 15:587, 1942–43.

6.
Hamilton-Paterson JL: Preleukaemic anemia. Acta Haematol 2:309, 1949.

7.
Block M, Jacobson LO, Bethard WJ: Preleukemic acute human leukemia. JAMA 152:1018, 1953.

8.
Vilter RW, Jarrold T, Will JJ, et al: Refractory anemia with hyperplastic bone marrow. Blood 15:1, 1960.

9.
Schiller M, Rachmilewitz EA, Izak G: Pancytopenia with hypercellular hemopoietic tissue. Isr J Med Sci 5:69, 1969.

10.
Saarni MI, Linman JW: Preleukemia. Am J Med 55:38, 1973.

11.
Linman JW, Saarni MI: The preleukemic syndrome. Semin Hematol 11:93, 1974.

12.
Pierre RV: Preleukemic states. Semin Hematol 11:73, 1974.

13.
Dreyfus B: Preleukemic states. Blood Cells 2:33, 1976.

14.
Linman JW, Bagby GC Jr: The preleukemic syndrome: clinical and laboratory features, natural course and management. Blood Cells 2:11, 1976.

15.
Linman JW, Bagby GC Jr: The preleukemic syndrome (hemopoietic dysplasia). Cancer 42:854, 1978.

16.
Bessis M, Bernard J: Hematopoietic dysplasias. Blood Cells 2:5, 1976.

17.
Bennett JM, Catovsky D, Daniel MT, et al: The chronic myeloid leukaemias: guidelines for distinguishing granulocytic, atypical chronic myeloid, and chronc myelomonocytic leukaemia. Br J Hematol 87:746, 1994.

18.
Van den Berghe H, Lovwagie A, Broeckart-Van Orshoven A, et al: Chromosome analyses in two unusual malignant blood disorders presumably induced by benzene. Blood 53:558, 1979.

19.
Askoy M, Erdem S: Follow-up study on the mortality and the development of leukemia in 44 pancytopenic patients with chronic exposure to benzene. Blood 52:285, 1978.

20.
Smith MT, Zhang L: Biomarkers of leukemic risk: benzene as a model. Environ Health Perspect 106(suppl 4):937, 1998.

21.
Kitahara M, Cosgriff TM, Eyre HJ: Sideroblastic anemia as a preleukemia event in patients treated for Hodgkin’s disease. Ann Intern Med 92:625, 1980.

22.
Pedersen-Bjergaard J, Ersbøll J, Sørensen HM, et al: Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin’s lymphomas. Ann Intern Med 103:195, 1985.

23.
Pedersen-Bjergaard J, Osterlind K, Hansen M, et al: Acute nonlymphocytic leukemia, preleukemia and solid tumors following intensive chemotherapy of small cell carcinoma of the lung. Blood 66:1393, 1985.

24.
Leone G, Mele L, Pulson A, Equitani F, Pagano L: The incidence of secondary leukemia. Haematologica 84:937, 1999.

25.
Felix CA: Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1400:233, 1998.

26.
Park DJ, Koeffler HP: Therapy-related myelodysplastic syndromes. Semin Hematol 33:256, 1996.

27.
Rigolin GM, Cuneo A, Roberti MG, et al: Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. Br J Haematol 103:189, 1998.

28.
Sterkers Y, Preudhomme C, Lai JL, et al: Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 91:616, 1998.

29.
Van Den Neste E, Louviaux I, Michaux JL, et al: Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br J Haematol 105:268, 1999.

30.
Nakanishi M, Tanaka K, Shintani T, et al: Chromosomal instability in acute myelocytic leukemia and myelodysplastic syndrome patients among atomic bomb survivors. J Radiat Res (Toyko) 40:159, 1999.

31.
Nowell P, Bergman G, Besa E, et al: Progressive preleukemia with a chromosomally abnormal clone in a kindred with the Estren-Damashek variant of Fanconi’s anemia. Blood 64:1135, 1984.

32.
Alter BP: Fanconi’s anemia and malignancies. Am J Hematol 53:99, 1996.

33.
McNAlly RJO, Rowland D, Roman E, Cartwright RA: Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 15:173, 1997.

34.
Aul C, Gatterman N, Schneider W: Age-related incidence and other epidemiologic aspects of myelodysplastic syndrome. Br J Haematol 82:358, 1992.

35.
Abkowitz JL, Fialkow PJ, Niebrugge DJ, et al: Pancytopenia as a clonal disorder of a multipotent hemopoietic stem cell. J Clin Invest 73:258, 1984.

36.
Rasking WH, Tirumali N, Jacobson R, et al: Evidence for a multistep pathogenesis of a myelodysplastic syndrome. Blood 63:1318, 1984.

37.
Prchal JT, Throckmorton DW, Caroll AJ, et al: A common progenitor for human myeloid and lymphoid cells. Nature 274:590, 1978.

38.
Mongkonsritragoon W, Letendre L, Li CY: Multiple lymphoid nodules in bone marrow have the same clonality as underlying myelodysplastic syndrome recognized with fluorescent in situ hybridization technique. Am J Hematol 59:252, 1998.

39.
Fialkow PJ: Cell lineages in hematopoietic neoplasia studied with glucose-6-phosphate dehydrogenase cell markers. J Cell Physiol J 1:37, 1982.

40.
Janssen JWG, Buschle M, Layton M, et al: Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 73:248, 1989.

41.
Tefferi A, Thibodeau SN, Solberg LA Jr: Clonal studies in the myelodysplastic syndrome using X-linked restriction fragment length polymorphisms. Blood 75:1770, 1990.

42.
Gerritsen WR, Donohue J, Bauman J, et al: Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage but not in the lymphoid lineage as detected by fluorescent in situ hybridization. Blood 80:217, 1992.

43.
Anastasi J, Fang J, LeBeau MM, et al: Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: lineage, response to growth factor therapy, and clone expansion. Blood 81:1580, 1993.

44.
Culligan DJ, Cachia P, Whittaker A, et al: Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 81:346, 1992.

45.
Abrahamson G, Boultwod J, Madden J, et al: Clonality of cell population in refractory anaemia using combined approach of gene loss and X-linked restricting fragment length polymorphism–methylation analysis. Br J Haematol 79:550, 1991.

46.
Delforge M, Demuynck H, Verhoef G, et al: Patients with high-risk myelodysplastic syndrome can have polyclonal or clonal haemopoiesis in complete haematological remission. Br J Haematol 102:486, 1998.

47.
Lawrence HJ, Broudy VC, Magenis RE, et al: Cytogenetic evidence for involvement of B-lymphocytes in acquired idiopathic sideroblastic anemia. Blood 70:1003, 1982.

48.
Hirai H, Okada M, Mizoguchi H, et al: Relationship between activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood 71:256, 1988.

49.
Nakagawa T, Saitoh S, Imoto S, et al: Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 49:114, 1992.

50.
VanKamp H, dePijper C, Verlaan-de Vries M, et al: Longitudinal analysis of point mutations of the N-ras protooncogene in patients with myelodysplasia using archival blood smears. Blood 79:1266, 1992.

51.
Paquette RL, Landau EM, Pierre RV, et al: N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82:590, 1993.

52.
Bartram CR: Molecular genetic aspects of myelodysplastic syndromes. Semin Hematol 33:139, 1996.

53.
Parker J, Mufti GJ: Ras and myelodysplasia: lessons from the last decade. Semin Hematol 33:206, 1996.

54.
Padua RA, Guinn BA, Al-Sabah AI, et al: RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12:887, 1998.

55.
Plata E, Viniou N, Abazis D, et al: Cytogenetic analysis and RAS mutations in primary myelodysplastic syndromes. Cancer Genet Cytogenet 111:124, 1999.

56.
Quesnel B, Guillerm G, Vereecque R, et al: Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985, 1998.

57.
Koeffler HP, Golde DW: Human preleukemia. Ann Intern Med 93:347, 1980.

58.
Raza A, Gezer S, Mundle S, et al: Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86:268, 1995.

59.
Rajapaksa R, Ginzton N, Rott LS, Greenberg PL: Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88:4275, 1996.

60.
Greenberg PL: Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 22:1123, 1998.

61.
Raza A, Alvi S, Broady-Robinson L, et al: Cell cycle kinetic studies in 68 patients with myelodysplastic syndromes following intravenous iodo- and/or bromodeoxyuridine. Exp Hematol 25:530, 1997.

62.
Gersuk GM, Beckham C, Loken MR, et al: A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 103:176, 1998.

63.
Mundle SD, Ali A, Cartlidge JD, et al: Evidence for involvement of tumor necrosis factor-alpha in apoptotic death of bone marrow cells in myelodysplastic syndromes. Am J Hematol 60:36, 1999.

64.
Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ: “Low-risk” myelodysplastic syndrome is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic bcl-2- related proteins. Br J Haematol 103:1075, 1998.

65.
Groupe Francais de Morphologie Hématologique: French registry of acute leukemia and myelodysplastic syndromes. Cancer 60:1385, 1987.

66.
Luna-Fineman S, Shannon KM, Atwater SK, et al: Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients. Blood 93:459, 1999.

67.
Hasle H, Jacobsen BB, Pedersen NT: Myelodysplastic syndromes in childhood: a population-based study of nine cases. Br J Haematol 81:495, 1992.

68.
Gadner H, Haas OA: Experience in pediatric myelodysplastic syndrome. Hematol Oncol Clin North Am 6:655, 1992.

69.
Martinez-Climent JA, Garcia-Conde J: Chromosomal rearrangements in childhood acute myeloid leukemia and myelodysplastic syndromes. J Pediatr Hematol Oncol 2191. 1999

70.
Li FP, Marchetto DJ, Vawter FG: Acute leukemia and preleukemia in eight males in a family: an X-linked disorder? Am J Hematol 6:61, 1979.

71.
Horwitz M, Sabath DE, Smithson WA, Radich J: A family inheriting different subtypes of acute myelogenous leukemia. Am J Hematol 52:295, 1996.

72.
Noel P, Solberg LA Jr: Myelodysplastic syndromes: pathogenesis, diagnosis and treatment. Crit Rev Oncol Hematol 12:193, 1992.

73.
Ahmad YH, Kiehl R, Papac RJ: Myelodysplasia. The clinical spectrum of 51 patients. Cancer 76:869, 1995.

74.
Zanger B, Dorsey HN: Fever—a manifestation of preleukemia. JAMA 236:1266, 1976.

75.
Varela BL, Chuang C, Woll JE, Bennett JM: Modifications in the classification of primary myelodysplastic syndrome. Hematol Oncol 3:55, 1985.

76.
Saxne T, Turesson I, Wallheim FA: Preleukemic syndrome simulating SLE. Acta Med Scand 212:421, 1982.

77.
Hebbar M, Hebbar-Savean K, Fenaux P: Systemic diseases in myelodysplastic syndromes. Rev Med Intern 16:897, 1995.

78.
Dezza L, Cazzola M, Bergamaschi G, et al: Myelodysplastic syndrome with monosomy 7 in adulthood. Haematologia 68:723, 1983.

79.
Montecucco C, Cazzola M, Ascari E: Diabetes insipidus in the preleukaemic phase of acute non-lymphocytic leukaemia. Scand J Haematol 33:326, 1985.

80.
Zijlstra F, Killinger D, Volpe R: Diabetes insipidus associated with dysplastic pancytopenia. Am J Med 82:339, 1987.

81.
Sweet RD: Acute neutrophilic dermatosis 1978. Br J Dermatol 100:93, 1979.

82.
Soppi E, Nousiainen T, Seppa A, et al: Acute febrile neutrophilic dermatosis (Sweet’s syndrome) in association with myelodysplastic syndromes: a report of three cases and a review of the literature. Br J Haematol 73:43, 1989.

83.
Arbetter KR, Hubbard KW, Markovic SN, et al: Case of granulocyte colony-stimulating factor-induced Sweet’s syndrome. Am J. Hematol 61:126, 1999.

84.
Arun B, Berberian B, Azumi N, et al. Sweets during treatment with all-trans retinoic acid in a patient with acute promyelocytic leukemia. Leuk Lymph 31:613, 1998.

85.
Avi I, Rosenbaum H, Levy Y, Rowe J: Myelodysplastic syndrome and associated skin lesions: a review of the literature. Leuk Res 23:323, 1999.

86.
Weber RFA, Geraedts JPM, Kerkhofs H, Leeksma CHW: The preleukemic syndrome. Acta Med Scand 207:391, 1980.

87.
Ohno E, Ohtsuka E, Watanabe K, et al: Behcet’s disease associated with myelodysplastic syndromes. A case report and a review of the literature. Cancer 79:262, 1997.

88.
Komatsuda A, Miura I, Ohtani H, et al: Crescentic glomerulonephritis accompanied by myeloperoxidase-antineutrophil cytoplasmic antibodies in a patient having myelodysplastic syndrome with trisomy 7. Am J Kidney Dis 31:336, 1998.

89.
Saitoh T, Murakami H, Uchiumi H, et al: Myelodysplastic syndromes with nephrotic syndrome. Am J Hematol 60:200, 1999.

90.
Harewood GC, Loftus EV Jr, Tefferi A, et al: Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm Bowel Dis 5:98, 1999.

91.
Clark RE, Payne HE, Jacobs A: Primary myelodysplastic syndrome and cancer. Br Med J 294:937, 1987.

92.
Sans-Sabrafen J, Buxó-Costa J, Woessner S, et al: Myelodysplastic syndromes and malignant solid tumors. Am J Hematol 41:1, 1992.

93.
Florensa L, Vallespi T, Woessner S, et al: Incidence and characteristics of lymphoid malignancies in untreated myelodysplastic syndromes. Leuk Lymphoma 23:609, 1996.

94.
Mitterbauer G, Schwarzmeier J, Mitterbauer M, Jaeger U, Fritsch G, Schwarzinger I: Myelodysplastic syndrome/acute myeloid leukemia supervening previously untreated chronic B-lymphocytic leukemia: demonstration of the concomitant presence of two different malignant clones by immunologic and molecular analysis. Ann Hematol 74:193, 1997.

95.
Craig JE, Sampietro M, Oscier DG, et al: Myelodysplastic syndrome with karyotype abnormality is associated with elevated F-cell production. Br J Haematol 93:601, 1996.

96.
Kornberg A, Goldfarb A: Preleukemia manifested by hemolytic anemia with pyruvate-kinase deficiency. Arch Intern Med 146:785, 1986.

97.
Heimstadter V, Arnold H, Blume KG, et al: Acquired pyruvate kinase deficiency with hemolysis in preleukemia. Acta Haematol 57:339, 1977.

98.
Lopez M, Bonnet-Gajdos M, Reviron M, et al: Acute leukemia augured before clinical signs by blood group antigen abnormalities and low levels of A and H blood group transferase activities in erythrocytes. Br J Haematol 63:535, 1986.

99.
Harris JW, Koscick R, Lazarus HM, et al: Leukemia arising out of paroxysmal nocturnal hemoglobinuria. Leuk Lymph 32:401, 1999.

100.
Anagnou NP, Ley TJ, Chesbro B, et al: Acquired a-thalassemia in preleukemia is due to decreased expression of all four a-globin genes. Proc Natl Acad Sci USA 80:6051, 1983.

101.
Helder J, Deisseroth A: S1 nuclease analysis of a-globin gene expression in preleukemic patients with acquired hemoglobin H disease after transfer to mouse erythroleukemia cells. Proc Natl Acad Sci USA 84:2387, 1987.

102.
Economopoulos T, Stathakis N, Maragoyannis Z, et al: Myelodysplastic syndrome. Clinical significance of monocyte concentration, degree of blastic infiltration and ring sideroblasts. Acta Haematol 65:97, 1981.

103.
Jaworkowsky LI, Solovey DY, Rhausova LY, Udris OY: Monocytosis as a sign of subsequent leukemia in patients with cytopenias (preleukemia). Folia Hematol 110:395, 1983.

104.
Friedland ML, Ward H, Wittels EG, Arlin ZA: A monocytic leukemoid reaction: a manifestation of preleukemia. Rhode Island Med J 68:173, 1985.

105.
Kuriyama K, Tomonaga M, Matsuo T, et al: Diagnostic significance of pseudo-Pelger-Huët anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol 63:665, 1986.

106.
Langenhuijsen MMAC: Neutrophils with ring-shaped nuclei in myeloproliferative disease. Br J Haematol 58:227, 1984.

107.
Clark RE, Smith SA, Jacobs A: Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid. J Clin Pathol 40:652, 1987.

108.
Cech P, Markert M, Perrin LH: Partial myeloperoxidase deficiency in preleukemia. Blut 47:21, 1983.

109.
Schofield KP, Stone PCW, Kelsey P, et al: Quantitative cytochemistry of blood neutrophils in myelodysplastic syndromes and chronic granulocytic leukaemia. Cell Biochem Funct 1:92, 1983.

110.
Elghetany MT, Peterson B, MacCallum J, et al: Deficiency of neutrophilic granule membrane glycoproteins in the myelodysplastic syndromes: a common deficiency in 216 patients studied by the Cancer and Leukemia Group B. Leuk Res 21:801, 1997.

111.
Ruutu P: Granulocyte function in myelodysplastic syndromes. Scand J Haematol 36(suppl 45):66, 1986.

112.
Prodan M, Tulissi P, Perticarari S, et al: Flow cytometric assay for the evaluation of phagocytosis and oxidative burst of polymorphonuclear leukocytes and monocytes in myelodysplastic disorders. Haematologica 80:212, 1995.

113.
Piva E, De Toni S, Caenazzo A, Pradella M, Pietrogrande F, Plebani M: Neutrophil NADPH oxidase activity in chronic myeloproliferative and myelodysplastic diseases by microscopic and photometric assays. Acta Haematol 94:16, 1995.

114.
Carulli G, Sbrana S, Minnucci S, et al: Actin polymerization in neutrophils from patients affected by myelodysplastic syndromes—a flow cytometric study. Leuk Res 21:513, 1997.

115.
Nakaseko C, Asai T, Wakita H, Oh H, Saito Y: Signalling defect in FMLP-induced neutrophil respiratory burst in myelodysplastic syndromes. Br J Haematol 95:482, 1996.

116.
Pamphilon DH, Aparicio SR, Roberts BE, et al: The myelodysplastic syndromes—a study of haemostatic function and platelet ultrastructure. Scand J Haematol 33:486, 1984.

117.
Payne CM, Glasser L: An ultrastructural morphometric analysis of platelet grant and fusion granules. Blood 67:299, 1986.

118.
Rasi V, Lintula R: Platelet-function in the myelodysplastic syndromes. Scand J Haematol 36(suppl 45):71, 1986.

119.
Hamblin TJ: Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 33:150, 1996.

120.
Anderson RW, Volsky DJ, Greenberg B, et al: Lymphocyte abnormalities in preleukemia. I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leuk Res 7:389, 1983.

121.
Kerndrup G, Meyer K, Ellegaard J, Hokland P: Natural killer (NK)-cell activity and antibody-dependent cellular cytotoxicity (ADCC) in primary preleukemic syndrome. Leuk Res 8:239, 1984.

122.
Takagi S, Kitagawa S, Takeda A, et al: Natural killer—interferon system in patients with preleukaemic states. Br J Haematol 58:71, 1984.

123.
Volsky DJ, Anderson RW: Deficiency in Epstein-Barr virus receptors on B lymphocytes of preleukemia patients. Cancer Res 43:3923, 1983.

124.
Knox SJ, Greenberg BR, Anderson RW, Rosenblatt LS: Studies of T lymphocytes in preleukemic disorders and acute nonlymphocytic leukemia: in vitro radiosensitivity, mitogenic responsiveness, colony formation, and enumeration of lymphocytic subpopulations. Blood 61:449, 1983.

125.
Baumann MA, Milson TJ, Patrick CW, et al: Immunoregulatory abnormalities in myelodysplastic disorders. Am J Hematol 22:17, 1986.

126.
Economopoulos T, Economidou J, Giannopoulos G, et al: Immune abnormalities in myelodysplastic syndromes. J Clin Pathol 38:908, 1985.

127.
Mufti GJ, Figes A, Hamblin TJ, et al: Immunological abnormalities in myelodysplastic syndromes. Br J Haematol 63:143, 1986.

128.
Tricot G, DeWolf-Peeters C, Vlietinck R, Verwilghen RL: The importance of bone marrow biopsy in myelodysplastic disorders. Bibl Hematol 50:31, 1984.

129.
Frisch B, Bartol R: Bone marrow histology in myelodysplastic syndromes. Scand J Haematol 36(suppl 45):21, 1986.

130.
Delacretaz F, Schmidt PM, Piguet D, et al: Histopathology and myelodysplastic syndromes: the FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol 87:180, 1987.

131.
Fohlmeister I, Fischer R, Modder B, et al: Aplastic anemia and hypocellular myelodysplastic syndrome. J Clin Pathol 38:1218, 1985.

132.
Reizenstein P, Lagerlof B, Skarberg KO, et al: Alterations in erythropoiesis preceding leukemia. Acta Haematol 54:152, 1975.

133.
Hast R: Studies on preleukemia. II. Clinical and prognostic significance of sideroblasts in regenerative anaemia with hypercellular bone marrow. Scand J Haematol 21:396, 1978.

134.
Hast R, Reizenstein P: Sideroblastic anemia and development of leukemia. Blut 42:203, 1981.

135.
Tricot G, Vlietinck R, Boogaerts MA, et al: Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy, and chromosomal analysis. Br J Haematol 60:19, 1985.

136.
Tricot G, DeWolf-Peeters C, Vlietinck R, Verwilghen RL: Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of ALIP in MDS. Br J Haematol 58:217, 1984. 151.

137.
Smith WB, Ablin A, Goodman JR, Brecher J: Atypical megakaryocytes in the preleukemic phase of AML. Blood 42:535, 1973.

138.
Queisser W, Queisser U, Ansmann M, et al: Megakaryocyte polypoloidization in acute leukemia and preleukemia. Br J Haematol 28:261, 1974.

139.
Bartl R, Frisch B, Baumgart R: Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspiratres and trephine biopsies. Leuk Res 16:15, 1992.

140.
Maschek H, Georgii A, Kaloutsi V, et al: Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients. Eur J Haematol l48:208, 1992.

141.
Greenberg PL: Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes. Semin Hematol 33:163, 1996.

142.
Chui DHK, Clarke BJ: Abnormal erythroid progenitor cells in human preleukemia. Blood 60:362, 1982.

143.
Senn JS, Messner HA, Pinkerton PH, et al: Peripheral blood blast cell progenitors in human preleukemia. Blood 59:106, 1982.

144.
Juvonen E, Partanen S, Knuutila S, Ruutu T: Megakaryocyte colony formation by bone marrow progenitors in myelodysplastic syndrome. Br J Haematol 63:331, 1986.

145.
Lidbeck J: In vitro colony and cluster growth haemopoietic dysplasia (the preleukaemic syndrome). I. Clinical correlations. Scand J Haematol 24:412, 1980.

146.
Raymakers R, DeWitte T, Joziasse J, et al: In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukemia. Br J Haematol 78:35, 1991.

147.
Konwalinka G, Peschel C, Schmalzl F, et al: CFU-GM assay, cytochemical and electron microscopic studies in agar in patients with preleukemia syndrome and aplastic anemia. Int J Cell Cloning 3:367, 1985.

148.
Koeffler HP, Golde DW: Cellular maturation in human preleukemia. Blood 52:355, 1978.

149.
Cambier N, Baruchel A, Schlageter MH, et al: Chronic myelomonocytic leukemia: from biology to therapy. Hematol Cell Ther 39:41, 1997.

150.
Aul C, Gatterman N, Schneider W: Comparison of in vitro growth characteristics of blast cell progenitors (CFU-BL) in patients with myelodysplastic syndromes and acute myeloid leukemia. Blood 80:625, 1992.

151.
Flores-Figueroa E, Gutierrez-Espindola G, Guerrero-Rivera S, Pizzuto-Chavez J, Mayani H: Hematopoietic progenitor cells from patients with myelodysplastic syndromes: in vitro colony growth and long-term proliferation. Leuk Res 23:385, 1999.

152.
Sato T, Kim S, Selleri C, Young NS, Maciejewski JP: Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome. Leukemia 12:1187, 1998.

153.
Aizawa S, Nakano M, Iwase O, et al: Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 23:239, 1999.

154.
Janowska-Wieczorek A, Bilch AR, Jacobs A: Increased circulating colony-stimulating factor-1 in patients with preleukemia, leukemia, and lymphoid malignancies. Blood 77:1796, 1991.

155.
Verhoef GEG, DeSchouder P, Ceuppens JL: Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 6:1268, 1992.

156.
Bowen D, Yancik S, Bennett L, et al: Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br J Haematol 85:63, 1993.

157.
Zwierzina H, Anderson JE, Rollinger-Holzinger I, Torok-Storb B, Nuessler V, Lyman SD: Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes. Leukemia 13:553, 1999.

158.
Tamura H, Ogata K, Luo S, et al: Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol 103:778, 1998.

159.
Parlier V, van Melle G, Beris Ph, et al: Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Cancer Genet Cytogenet 78:219, 1994.

160.
Jacobs RH, Cornbleet MA, Vordiman JW, et al: Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 67:1765, 1986.

161.
de Greef GE, Hagemeijer A: Molecular and cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndromes. Ballière’s Clin Hematol 9:1, 1996.

162.
Fenaux P, Morel P, Lai JL: Cytogenetics of myelodysplastic syndromes. Semin Hematol 33:127, 1996.

163.
Solé F, Prieto L, Badia L, et al: Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes. Cancer Genet Cytogenet 64:12, 1992.

164.
Estey E, Trujillo JM, Cork A, et al: AML-associated cytogenetic abnormalities (inv 16), del (16), t(8;21) in patients with myelodysplastic syndromes. Hematol Pathol 6:43, 1992.

165.
Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86:3542, 1995.

166.
Jotterand M, Parlier V: Diagnostic and prognostic significance of cytogenetics in adult primary myelodysplastic syndromes. Leuk Lymphoma 23:253, 1996.

167.
Zhang L, Rothman N, Wang Y, et al: Increased aneusomy and long arm deletion of chromosomes 5 and 7 in the lymphocytes of chinese workers exposed to benzene. Carcinogenesis 19:1955, 1998.

168.
Nimer SD, Golde DW: The 5q- abnormality. Blood 70:1705, 1987.

169.
Boultwood J, Fidler C, Soularue P, et al: Novel genes mapping to the critical region of the 5q-syndrome. Genomics 45:88, 1997.

170.
Antillon F, Raimondi SC, Fairman J, et al: 5q- in a child with refractory anemia with excess blasts: similarities to 5q-syndrome in adults. Cancer Genet Cytogenet 105:119, 1998.

171.
Horrigan SK, Westbrook CA, Kim AH, Banerjee M, Stock W, Larson RA: Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood 88:2665, 1996.

172.
Huebner K, Isobe M, Croce CM, et al: The human gene encoding GM-CSF is at 5q21–q32, the chromosome region deleted in the 5q-anomaly. Science 230:1281, 1985.

173.
LeBeau MM: Deletions of chromosome 5 in malignant myeloid disorders. Cancer Surv 15:143, 1992.

174.
Morris SW, Valentine MB, Shapiro DN, et al: Reassignment of the human CSF1 gene to chromosome 1p13–p21. Blood 78:2013, 1991.

175.
Nienhuis AW, Bunn HF, Turner PH, et al: Expression of the human c-fms proto-oncogene in hematopoietic cells and its deletion in the 5q- syndrome. Cell 42:421, 1985.

176.
LeBeau MM, Westbrook CA, Diaz MO, et al: Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. Science 231:984, 1986.

177.
Willman CL, Sever CE, Pallavicini MG, et al: Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259:968, 1993.

178.
Boultwood J, Fidler C, Lewis S, et al: Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q-chromosome in some patients with the 5q-syndrome. Blood 82:2611, 1993.

179.
Jaju RJ, Boultwood J, Oliver FJ, et al: Molecular cytogenetic delineation of the critical deleted region in the 5q-syndrome. Genes Chromosomes Cancer 22:251, 1998.

180.
Boultwood J, Fidler C, Lewis S, et al: Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q-chromosome in some patients with the 5q-syndrome. Blood 82:2611, 1993.

181.
Harada H, Kitagawa M, Tanaka N, et al: Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 259:971, 1993.

182.
Pedersen B, Jensen IM: Clinical and prognostic implications of chromosome 5q deletions: 96 high-resolution-studied patients. Leukemia 5:566, 1991.

183.
Mathew P, Tefferi A, Dewald GW, et al: The 5q-syndrome. A single-institution study of 43 consecutive patients. Blood 81:1040, 1993.

184.
Michiels JJ, Mallios-Zorbala H, Prins MEF, et al: Simple monosomy 7 and myelodysplastic syndrome in thirteen patients without previous cytostatic treatment. Br J Haematol 64:425, 1986.

185.
Pasquali F, Bernasconi P, Cosalone R, et al: Pathogenetic significance of “pure” monosomy 7 in myeloproliferative disorders. Analysis of 14 cases. Hum Genet 62:40, 1982.

186.
Dohner K, Brown J, Hehmann U, et al: Molecular cytogenetic characterization of a critical region in bands 7q35-q36 commonly deleted in malignant myeloid disorders. Blood 92:4031, 1998.

187.
Sessarego M, Fugazza G, Gobbi M, et al: Complex structural involvement of chromosome 7 in primary myelodysplastic syndromes determined by fluorescence in situ hybridization. Cancer Genet Cytogenet 106:110, 1998.

188.
Hayashi Y, Egushi M, Sugita K, et al: Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferation disorder in Down’s syndrome. Blood 72:15, 1988.

189.
Berger R, LeConiat M, Schaison G: Chromosome abnormalities in bone marrow of Fanconi anemia patients. Cancer Genet Cytogenet 65:47, 1993.

190.
Bernstein R, Philip P, Ueshima Y: Fourth international workshop on chromosomes in leukemia, 1982. Abnormalities of chromosome 7 resulting in monosomy 7 or in deletion of the long arm (7q-): review of translocations, breakpoints, and associated abnormalities. Cancer Genet Cytogenet 11:300, 1984.

191.
Smadja N, Krulik M, DeGramont A, et al: Translocation 1;7 in preleukemic states. Cancer Genet Cytogenet 18:189, 1985.

192.
Woloschak GF, Dewald GW, Gahn RS, et al: Amplification of RNA and DNA specific for erb B in unbalanced 1;7 chromosomal translocation associated with myelodysplastic syndrome. J Cell Biochem 32:23, 1986.

193.
Canellos GP, Whang-Peng J: Philadelphia-chromosome-positive preleukemic state. Lancet 2:1227, 1972.

194.
Roth DG, Richman CM, Rowley JD: Chronic myelodysplastic syndrome (preleukemia) with the Philadelphia chromosome. Blood 56:262, 1980.

195.
Bjorkman SE: Chronic refractory anemia with sideroblastic bone marrow. A study of four cases. Blood 11:250, 1956.

196.
Caroli J, Bernard J, Bessis M, et al: Hémochromatoses avec anémie hypochrome et absence d’hémoglobine anormale. Presse Med 65:1991, 1957.

197.
Singh AK, Shinton NK, Williams JDF: Ferrokinetic abnormalities and their significance in patients with sideroblastic anaemia. Br J Haematol 18:67, 1970.

198.
Barry WE, Day HJ: Refractory sideroblastic anemia: clinical and hematologic study of ten cases. Ann Intern Med 61:1029, 1964.

199.
Kushner JP, Lee GR, Wintrobe MM, et al: Idiopathic refractory sideroblastic anemia. Medicine 50:139, 1971.

200.
Geschke W, Beutler E: Refractory sideroblastic and non-sideroblastic anemia. West J Med 127:85, 1977.

201.
Cotter PD, May A, Fitzsimons EJ, et al: Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest 96:2090, 1995.

202.
Gattermann N, Retzlaff S, Wang YL, et al: A heteroplasmic point mutation of mitochondrial tRNALeu(CUN) in non-lymphoid haemopoietic cell lineages from a patient with acquired idiopathic sideroblastic anaemia. Br J Haematol 93:845, 1996.

203.
Bowen DT, Jacobs A: Primary acquired sideroblastic erythropoiesis in non-anaemic and minimally anaemic subjects. J Clin Pathol 42:56, 1989.

204.
Beris PH, Graf J, Miescher PA: Primary acquired sideroblastic and primary acquired refractory anemia. Semin Hematol 20:101, 1983.

205.
Garand R, Gardars J, Bizet M, et al: Heterogeneity of acquired idiopathic sideroblastic anema (AISA). Leuk Res 16:463, 1992.

206.
Kitahara M, Cosgriff TM, Eyre HJ: Sideroblastic anemia as a preleukemic event in patients treated for Hodgkin’s disease. Ann Intern Med 92:625, 1980.

207.
Kardos G, Veerman AJ, de Waal FC, van Oudheusden LJ, Slater R: Familial sideroblastic anemia with emergence of monosomy 5 and myelodysplastic syndrome. Med Pediatr Oncol 26:54, 1996.

208.
Yoshida Y, Oguma S, Tohyama K, et al: Diagnostic and biological significance of sideroblastic erythropoiesis in the myelodysplastic syndromes. Int J Hematol 67:137, 1998.

209.
Mecucci C, VanOrshoven A, Vermaelen K, et al: 11 q-chromosome is associated with abnormal iron stores in myelodysplastic syndromes. Cancer Genet Cytogenet 27:39, 1987.

210.
Schulman P, Kardon N, Weiner R, et al: Acquired idiopathic sideroblastic anemia: a new chromosomal abnormality. Cancer Genet Cytogenet 9:341, 1983.

211.
Bitran J, Golomb H, Rowley J: Idiopathic refractory sideroblastic anemia: banded chromosome analysis in six patients. Acta Haematol 57:15, 1977.

212.
Berrebi A, Bruck R, Shtalrid M, Chemke J: Philadelphia chromosome in idiopathic acquired sideroblastic anemia. Acta Haematol 72:343, 1984.

213.
Carroll AJ, Poon M-C, Robinson NC, Christ WM: Sideroblastic anemia associated with thrombocytosis and a chromosome 3 abnormality. Cancer Genet Cytogenet 22:183, 1986.

214.
Bennett DD, Stanley WS, Johnson CB: Combined phenotypic and genotypic analysis of ringed sideroblasts in acquired idiopathic sideroblastic anemia. Acta Haematol 73:235, 1985.

215.
Dewald GW, Pierre RV, Phyliky RL: Three patients with structurally abnormal X chromosomes, each with X q13 breakpoints and a history of idiopathic acquired sideroblastic anemia. Blood 59:100, 1982.

216.
DeWald GW, Brecher M, Travis LB, Stupea PJ: Twenty-six patients with hematologic disorders and X-chromosome abnormalities. Cancer Genet Cytogenet 42:173, 1989.

217.
Chabannori G, Molina L, Pegouri-Bandelier B, et al: A review of 76 patients with myelodysplastic syndromes treated with danazol. Cancer 73:3073, 1994.

218.
Musto P, Catalano L, Andriani A, et al: Recombinant erythropoietin for refractory anemia with ring sideroblasts. Hematologia 77:185, 1992.

219.
Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92:68, 1998.

220.
Cazzola M, Barosi G, Gobbi PG, et al: Natural history of idiopathic refractory sideroblastic anemia. Blood 71:305, 1988.

221.
Cartwright GE, Edwards CG, Skolnick MH, Amos BD: Association of HLA-linked hemochromatosis with idiopathic refractory sideroblastic anemia. J Clin Invest 65:980, 1980.

222.
Beris P, Samii K, Darbellay R, et al: Iron overload in patients with sideroblastic anaemia is not related to the presence of the haemochromatosis Cys282Tyr and His63Asp mutations. Br J Haematol 104:97, 1999.

223.
Weintraub LR, Conrad ME, Crosby WH: Iron-loading anemia. Treatment with repeated phlebotomy and pyridoxine. N Engl J Med 175:169, 1966.

224.
French TJ, Jacobs P: Sideroblastic anemia associated with iron overload treated by repeated phlebotomy. S Afr Med J 50:594, 1976.

225.
Jensen PD, Heickendorff L, Pedersen B, et al: The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 94:288, 1996.

226.
Lewy RI, Kansu E, Gabuzda T: Leukemia in patients with acquired idiopathic sideroblastic anemia. Am J Hematol 6:323, 1979.

227.
Cheng DS, Kushner JP, Wintrobe MM: Idiopathic refractory sideroblastic anemia. Incidence and risk factors for leukemic transformation. Cancer 44:724, 1979.

228.
Hast R, Reizenstein P: Sideroblastic anemia and development of leukemia. Blut 42:203, 1981.

229.
Streeter RR, Presant CA, Reinhard E: Prognostic significance of thrombocytosis in idiopathic sideroblastic anemia. Blood 50:427, 1977.

230.
Barton JC, Conrad ME, Parmley R: Acute lymphoblastic leukemia in idiopathic refractory sideroblastic anemia. Am J Hematol 9:109, 1980.

231.
Cazzola M, Barosi G, Gobbi PG: Natural history of idiopathic refractory sideroblastic anemia. Blood 71:305, 1988.

232.
Gatterman N, Aul C, Schneider W: Two types of acquired idopathic sideroblastic anemia (AISA). Br J Haematol 74:45, 1990.

233.
Greenberg P, Cox C, LeBeau MM, et al: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079, 1997.

234.
Feuaux P, Estienne MH, Lepelley P, et al: Refractory anemia according to the FAB classification: a report on 69 cases. Eur J Haematol 40:318, 1988.

235.
Weisdorf DJ, Oken MM, Johnson LJ, Rydell RE: Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukemia. Br J Haematol 55:691, 1983.

236.
Vilter RW, Will JJ, Jarrold T: Refractory anemia with hyperplastic bone marrow (regenerative anemia). Semin Hematol 4:175, 1967.

237.
Rosati S, Mick R, Xu F, et al: Refractory cytopenia with multilineage dysplasia: further characterization of an ‘unclassifiable’ myelodysplastic syndrome. Leukemia 10:20, 1996.

238.
Matsuda A, Jinnai I, Yagasaki F, et al: Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia. Leukemia 12:482, 1998.

239.
Zon LI, Arkin C, Groopman JE: Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol 66:251, 1987.

240.
Thiele J, Zirbas TK, Bertsch HP, et al: AIDS-related bone marrow lesions—myelodysplastic features or predominant inflammatory-reactive changes (HIV-myelopathy)? A comparative morphometric study by immunohistochemistry with special emphasis on apoptosis and PCNA-labeling. Anal Cell Path 11:141, 1996.

241.
Haznedar R: Pancytopenia with hypercellular bone marrow as a possible paraneoplastic syndrome. Am J Hematol 19:205, 1985.

242.
List AF, Brasfield F, Heaton R, et al: Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 90:3364, 1997.

243.
Freifeld A, Marchigiani D, Walsh T, et al: A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305, 1999.

244.
Malik IA, Moid I, Aziz Z, Khan S, Suleman M: A randomized comparison of fluconazole with amphotercin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med 105: 478, 1998.

245.
Bagby GC, Gabourel JD, Linman JW: Glucocorticoid therapy in the preleukemic syndrome. Ann Intern Med 92:55, 1980.

246.
Watts EJ, Majer RV, Grun PJ: Hyperfibrotic myelodysplasia: a report of three cases showing haematologic remission following treatment with prednisone. Br J Haematol 78:120, 1991.

247.
Schuster MW: Will cytokines alter the treatment of myelodysplastic syndrome? Am J Med Sci 305:72, 1993.

248.
Schouten HC, Vallenga E, Van Rhinen DJ, et al: Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 5:432, 1991.

249.
Stein RS, Abels RI, Krantz SB: Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 78:1658, 1991.

250.
Rafanelli D, Grossi A, Longo G, et al: Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia 6:323, 1992.

251.
Willemze R, vanderLaly N, Zwierzina H, et al: A randomized phase I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. Ann Hematol 64:173, 1992.

252.
Gradisher WJ, LeBeau MM, O’Laughlin R, et al: Clinical and cytogenetic responses to granulocyte-macrophage colony-stimulating factor in therapy-related myelodysplasia. Blood 80:2463, 1992.

253.
Negrin RS, Haeuber DH, Nagler A, et al: Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 76:36, 1990.

254.
Yoshida Y, Hirashima K, Asano S: A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes. Br J Haematol 78:378, 1991.

255.
Bessho M, Itho Y, Kataumi S: A hematologic remission by clonal hematopoiesis after treatment with recombinant human granulocyte-macrophage colony-stimulating factor and erythropoietin in a patient with therapy-related myelodysplastic syndrome. Leuk Res 16:123, 1992.

256.
Ganser A, Seipelt G, Lindemann A, et al: Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes. Blood 76:455, 1990.

257.
Ganser A, Hoelzer D: Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. Semin Hematol 33:186, 1996.

258.
Meyerson HJ, Farhi DC, Rosenthal NS: Transient increase in blasts mimicking acute leukemia and progressing myelodysplasia in patients receiving growth factor [see comments]. Am J Clin Pathol 109:675, 1998.

259.
Jonasova A, Neuwirtova R, Cermak J, et al: Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100:304, 1998.

260.
Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ: Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor V-beta profiles. Br J Haematol 102:1314, 1998.

261.
Coiffier B, Adeleine P, Viala JJ, et al: Dysmyelopoietic syndromes: a search for prognostic factors in 193 patients. Cancer 52:83, 1983.

262.
Garcia S, Sanz MA, Amigo V, et al: Prognostic factors in chronic myelodysplastic syndromes: a multivariate analysis in 107 cases. Am J Hematol 27:163, 1988.

263.
Minke DM, Colon-Otero G, Cockerill KJ, et al: Refractory thrombocytopenia: a myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. Am J Clin Pathol 98:502, 1992.

264.
Hoffman R: Acquired pure amegakaryocytic thrombocytopenia purpura. Semin Hematol 28:303, 1991.

265.
Welte K, Boxer LA: Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol 34:267, 1997.

266.
Rosen RB, Kang SJ: Congenital agranulocytosis terminating in acute myelomonocytic leukemia. J Pediatr 94:406, 1979.

267.
Smith OP, Hann IM, Chessells JM, et al: Haematological abnormalities in Shwachman-Diamond syndrome. Br J Haematol 94:279, 1996.

268.
Pearson HA, Lobel JS, Kocoshis SA, et al: A new syndrome of refractory sideroblastic anemia with vacuolization of marrow precursors and exocrine pancreatic dysfunction. J Pediatr 95:976, 1979.

269.
Orlandi E, Alessandrino EP, Caldera D, Bernasconi C: Adult leukemia after aplastic anemia: report of 8 cases. Acta Haematol 79:174, 1988.

270.
DePlanque MM, Bacigalupo A, Wüsch A, et al: Long-term follow up of severe aplastic anemia patients treated with antithymocyte globulin. Br J Haematol 73:121, 1989.

271.
Dunn DE, Tanawattanacharoen P, Boccuni P, et al: Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med 131:401, 1999.

272.
Doyle JA, Ginsburg WW: Eosinophilic fasciitis. Med Clin North Am 73:1157, 1989.

273.
Lakhanpal S, Ginsburg WW, Michet CJ, et al: Eosinophilic fasciitis: clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum 17:221, 1988.

274.
Naschitz JE, Boss JH, Misselevich I, et al: The fasciities-panniculitis syndromes. Clinical and pathologic features. Medicine 75:6, 1996.

275.
Kim SW, Rice L, Champlin R, Udden MM: Aplastic anemia in eosinophilic fasciitis: response to immunotherapy and marrow transplantation. Haematologia 28:131, 1997.

276.
Joseph AS, Cinkotal KI, Hunt L, Geary CG: Natural history of smoldering leukemia. Br J Cancer 46:160, 1982.

277.
Greenberg PL: The smoldering myeloid leukemic states: clinical and biological features. Blood 61:1035, 1983.

278.
Maddox A-M, Keating MJ, Smith TL, et al: Prognostic factors for survival of 194 patients with low infiltrate leukemia. Leuk Res 10:995, 1986.

279.
Najean Y, Pecking A: Refractory anemia with excess of myeloblasts in the bone marrow. A clinical trial of androgens in 90 cases. Br J Haematol 37:23, 1977.

280.
Lavessi AM, Maiolo AT, Chiorboli O, Mozzana R: The bone marrow karyotype in seventeen cases of refractory anemia with excess blasts (RAEB). Ann Genet 26:220, 1983.

281.
Foucar K, Langdon RM II, Armitage JO, et al: Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer 56:553, 1985.

282.
Hiddemann W, Jahns-Streubel G, Verbeek W, Wormann B, Haase D, Schoch C: Intensive therapy for high-risk myelodysplastic syndromes and the biological significance of karyotype abnormalities. Leuk Res 22 (suppl 1):S23, 1998.

283.
Invernizzi R, Pecci A, Rossi G, et al: Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes. Haematologica 82:660, 1997.

284.
Kuriya S, Murai K, Miyairi Y, et al: A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study. Cancer 78:422, 1996.

285.
Estey EH: Incorporating new modalities into guidelines. Topotecan for myelodysplastic syndromes. Oncology 12:81, 1998.

286.
Estey EH, Thall PF, Pierce S, et al: Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/– all-trans retinoic acid +/– granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93:2478, 1999.

287.
Silverman LR, Holland JF, Weinberg RS, et al: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 (suppl 1):21, 1993.

288.
Zagonel V, Lo Re G, Marotta G, et al: 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7 (suppl 1):30, 1993.

289.
Cheson BD: Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leuk Res 22 (suppl 1):S17, 1998.

290.
Gassmann W, Schmitz N, Loffler H, De Witte T: Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Semin Hematol 33:196, 1996.

291.
Appelbaum FR, Anderson J: Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 12 (suppl 1):S25, 1998.

292.
Runde V, de Witte T, Arnold R, et al: Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 21:255, 1998.

293.
Wattel E, Solary E, Leleu X, et al: A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d’etude des Leucemies aigues myeloides. Leukemia 13:524, 1999.

294.
Hellström-Lindberg E, Robért K-H, Gahrton G, et al: A predictive model for the clincal response to low dose ARA-C: a study of 102 patients with myelodysplastic syndromes and acute leukemia. Br J Haematol 81:503, 1992.

295.
Ganser A, Seipelt G, Eder M, et al: Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs. Semin Oncol 19:95, 1992.

296.
Wattel E, Guerci A, Hecquet B, et al: A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group. Blood 88:2480, 1996.

297.
Ogata K, Yamada T, Ito T, et al: Low-dose etoposide: a potential therapy for myelodysplastic syndromes. Br J Haematol 82:354, 1992.

298.
Nagler A, Rikilis I, Tatarsky I, Fabian I: Effect of 1,25-dihydroxyvitamin D3 and 13-cis-retinoic acid on in vitro hematopoiesis in the myelodysplastic syndromes. J Lab Clin Med 110:237, 1987.

299.
Rowinsky EK, Conley BA, Jones RJ, et al: Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. Leukemia 6:526, 1992.

300.
List AF: Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS? Leuk Res 22 (suppl 1):S7, 1998.

301.
Andreeff M, Stone R, Michaeli J, et al: Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 80:2604, 1992.

302.
Hast R, Lauren SAL, Reizenstein P: Absent clinical effects of retinoic acid and isotretinoin treatment on the myelodysplastic syndrome. Hematol Oncol 7:297, 1989.

303.
Ohno R, Naoe T, Hirano M, et al: Treatment of myelodysplastic syndromes with all-trans retinoic acid. Blood 81:1152, 1993.

304.
Richard C, Mazo E, Cuadrado MA, et al: Treatment of myelodysplastic syndrome with 1,25-dihydroxyvitamin D3. Am J Med 23:175, 1986.

305.
Motomura S, Kanamori H, Maruta A, et al: The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 38:67, 1991.

306.
Yoshida Y: Japanese experience in the treatment of myelodysplastic syndromes. Hematol Oncol Clin North Am 6:673, 1992.

307.
Paquette RL, Koeffler HP: Differentiation therapy. Hematol Oncol Clin North Am 6:687, 1992.

308.
DeRosa L, Montuoro A, DeLaurenzi A: Therapy of “high risk” myelodysplastic syndromes with an association of low-dose ara-c, retinoic acid and 1,25-dihydroxyvitamin D3. Biomed Pharmacother 46:211, 1992.

309.
Gisslinger H, Chott H, Linkesch W, et al: Long term a interferon therapy in myelodysplastic syndromes. Leukemia 4:91, 1990.

310.
Mailo AT, Cortelezzi A, Calori R: Recombinant g-interferon as first line therapy for high risk myelodysplastic syndromes. Leukemia 4:480, 1990.

311.
Nand S, Ellis T, Messmore H, et al: Phase II trial of recombinant human interferon-a in myelodysplastic syndromes. Leukemia 6:220, 1992.

312.
Holcombe RF: Mini-dose interferon-a-2a in the treatment of myelodysplasia. Leukemia 7:192, 1993.

313.
Maerevoet M, Van Den Neste E, Delannoy A, et al: Limited activity of mini-dose interferon alpha-2a in the treatment of myelodysplastic syndrome. Leuk Lymphoma 21:519, 1996.

314.
Petti MC, Latagliata R, Avvisati G, et al: Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon. Br J Haematol 95:364, 1996.

315.
Toze CL, Barnett MJ, Klingeman H-G: Response of therapy-related myelodysplasia to low-dose interleukin-2. Leukemia 7:463, 1993.

316.
Nand S, Stock W, Stiff P, Sosman J, Martone B, Radvany R: A phase II trial of interleukin-2 in myelodysplastic syndromes. Br J Haematol 101:205, 1998.

317.
Goy A, Belanger C, Casadevall N, et al: High doses of intravenous recombinant erythropoietin for the treatment of anemia in myelodysplastic syndrome. Br J Haematol 84:232, 1993.

318.
Vadhan-Raj S, Keating M, LeMaistre A, et al: Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317:1545, 1987.

319.
Verhoef G, VandDenBerghe HV, Boogaerts M: Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors. Leukemia 6:766, 1992.

320.
Tohyama K, Ohmori S, Michishita M: Effects of recombinant G-CSF and GM-CSF on in vitro differentiation of the blast cells of RAEB and RAEB-T. Eur J Haematol 42:348, 1989.

321.
Ferrero D, Bruno B, Pregno P, et al: Combined differentiating therapy for myelodysplastic syndromes: a phase II study. Leuk Res 20:867, 1996.

322.
Hofmann WK, Ganser A, Seipelt G, et al: Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor. Ann Hematol 78:125, 1999.

323.
Demuynck H, Verhoef GE, Zachee P, et al: Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant 17:745, 1996.

324.
Anderson JE, Appelbaum FR, Schoch G, et al: Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol 14:220, 1996.

325.
Demuynck H, Delforge M, Verhoef GE, et al: Feasibility of peripheral blood progenitor cell harvest and transplantation in patients with poor-risk myelodysplastic syndromes. Br J Haematol 92:351, 1996.

326.
De Witte T, Van Biezen A, Hermans J, et al: Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Blood 90:3853, 1997.

327.
Woolfrey AE, Gooley TA, Sievers EL, et al: Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood 92:3546, 1998.

328.
Arnold R, de Witte T, van Biezen A, et al: Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group. Bone Marrow Transplant 21:1213, 1998.

329.
Nevill TJ, Fung HC, Shepherd JD, et al: Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 92:1910, 1998.

330.
Testoni N, Lemoli RM, Martinelli G, et al: Autologous peripheral blood stem cell transplantation in acute myeloblastic leukaemia and myelodysplastic syndrome patients: evaluation of tumour cell contamination of leukaphereses by cytogenetic and molecular methods. Bone Marrow Transplant 22:1065, 1998.

331.
Wattel E, Solary E, Leleu X, et al: A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d’etude des Leucemies aigues myeloides. Leukemia 13:524, 1999.

332.
Sanz GF, Sanz MA, Vallespi T, et al: Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 74:395, 1989.

333.
Ganser A, Hoelzer D: Clinical course of myelodysplastic syndromes. Hematol Oncol Clin North Am 6:607, 1992.

334.
White AD, Culligan DJ, Hoy TG, Jacobs A: Extended cytogenetic follow-up of patients with myelodysplastic syndrome (MDS). Br J Haematol 81:499, 1992.

335.
Mufti GJ: A guide to risk assessment in the primary myelodysplastic syndrome. Hematol Oncol Clin North Am 6:587, 1992.

336.
Pfeilstocker M, Reisner R, Nosslinger T, et al: Cross validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics. Br J Haematol 106:455, 1999.

337.
Brown ER, Heerma NA, Tricot G: Spontaneous remission in myelodysplastic syndrome. Cancer Genet Cytogenet 46:125, 1990.

338.
Brusamolino E, Isernia P, Alessandrino EP, et al: Terminal deoxynucleotidyl transferase–positive acute leukemias evolving from a myelodysplastic syndrome. Am J Hematol 20:187, 1985.

339.
Berneman ZN, Van Bockstaele D, DeMeyer P, et al: A myelodysplastic syndrome preceding acute lymphoblastic leukaemia. Br J Haematol 60:353, 1985.

340.
Ascensao JL, Kay NE, Wright JJ, et al: Lymphoblastic transformation of myelodysplastic syndrome. Am J Hematol 22:431, 1986.

341.
Bonati A, Delia D, Starcich R: Progression of a myelodysplastic syndrome to pre-B-acute lymphoblastic leukaemia with unusual phenotype. Br J Haematol 64:487, 1986.

342.
Dayton MA, VanBesien K, Tricot G, et al: Preleukemic state preceding adult acute lymphoblastic leukemia. Am J Med 89:657, 1990.

343.
Saarinen UM, Wegelius R: Preleukemic syndrome in children. Report of four cases and review of literature. Am J Pediatr Hematol Oncol 6:137, 1984.

344.
Breatnach F, Chessells JM, Greaves MF: The aplastic presentation of childhood leukemia: a feature of common ALL. Br J Haematol 49:387, 1981.

345.
Klingemann H-G, Storb R, Sanders J, et al: Acute lymphoblastic leukaemia after bone marrow transplantation for aplastic anaemia. Br J Haematol 63:47, 1986.

346.
Nakamori Y, Takahashi M, Moriyama Y, et al: The aplastic presentation of adult acute lymphoblastic leukaemia. Br J Haematol 62:782, 1986.

347.
Homans AC, Cohen JL, Barker BE, Marzur EM: Aplastic presentation of acute lymphoblastic leukemia: evidence for cellular inhibition of normal hematopoietic progenitors. Am J Pediatr Hematol Oncol 11:456, 1989.

348.
DeAlarcon P, Miller M, Stuart MJ: Erythroid hypoplasia: an unusual presentation of childhood leukemia. Am J Dis Child 132:763, 1978.

349.
Reid MM, Summerfield GP: Distinction between aleukaemic prodrome of childhood acute lymphoblastic leukaemia and aplastic anemia. J Clin Pathol 45:697, 1992.

350.
MacSween JM, Langley GR: Light-chain disease and sideroblastic anemia–preleukemic chronic granulocytic leukemia. Can Med Assoc J 106:995, 1972.

351.
Trachida L, Palutke M, Poylik MD, Prasad AS: Primary acquired sideroblastic anemia preceding monoclonal gammopathy and malignant lymphoma. Am J Med 55:559, 1973.

352.
Papayannis AG, Stathakis NE, Kyrkou K, et al: Primary acquired sideroblastic anemia associated with chronic lymphocytic leukemia. Br J Haematol 28:125, 1974.

353.
Berkowitz LR, Ross DW, Orringe EP: Hairy cell leukemia with acquired dyserythropoiesis. JAMA 140:554, 1980.

354.
Catovsky D, Shaw MT, Hoffbrand AV, Dacie JV: Sideroblastic anemia and its association with leukemia and myelomatosis. A report of five cases. Br J Haematol 20:385, 1971.

355.
Dahlke MA, Nowell PC: Chromosomal abnormalities and dyserythropoiesis in the preleukaemic phase of multiple myeloma. Br J Haematol 31:111, 1975.

356.
Meckenstock G, Bonatsch CH, Heyll A, et al: T-cell receptor a/d expressing acute leukemia emerging from sideroblastic anemia: morphologic, immunological, and cytogenetic features. Leuk Res 16:379, 1992.

357.
Khaleeli M, Keane WM, Lee GR: Sideroblastic anemia in multiple myeloma. A preleukemic change. Blood 41:17, 1973.

358.
Greenberg BR, Miller C, Cardoff RD, et al: Concurrent development of preleukaemic lymphoproliferative and plasma cell disorders. Br J Haematol 53:125, 1983.

359.
Copplestone JA, Mufti GJ, Hamblin TJ, Oscier DG: Immunological abnormalities in myelodysplastic syndromes. Br J Haematol 63:149, 1986.

360.
Nevitzky N, Prindull G: For the European Society of Paediatric Haematology and Immunology: Myelodysplastic syndromes in children. Am J Hematol 63:212, 2000.

361.
Bauduer F, Ducout L, Dastuque N, et al: Epidemiology of myelodysplastic syndromes in a French general hospital of the Basque country. Leuk Res 22:205, 1998.

362.
Kumar T, Mandla SG, Greer WL: Familial myelodysplastic syndrome with early age of onset. Am J Hematol 64:53, 2000.

363.
Krishnan A, Bhatia S, Slovak ML, et al: Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma. Blood 95:1588, 2000.

364.
Abruzzese E, Radford JE, Miller JS, et al: Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood 94:1814, 2000.

365.
Vallespi T, Imbert M, Mecucci C, et al: Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica 83:258, 1998.

366.
Mecucci C, La Starza R: Cytogenetics of myelodysplastic syndromes. Forum 9:4, 1999.

367.
Rossi G, Pelizzari AM, Bellotti D, et al: Cytogenetic analogy between myelodysplastic syndrome and acute myeloid leukemia of elderly patients. Leukemia 14:636, 2000.

368.
Raza A, Qaui H, Lisak L, et al: Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 95:1580, 2000.

369.
Thomas DA: Pilot studies of thalidomide in acute myelogenous leukemia, myelodysplastic syndromes, and myeloproliferative disorders. Sem Hematol 37:26, 2000.

370.
Sanz GF, Sanz MA: Progress in intensive chemotherapy for high-risk myelodysplastic syndromes. Forum 9:63, 1999.

371.
Thompson JA, Gilliland DG, Prchal JT, et al: Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. Blood 95:1175, 2000.

372.
Deeg HG, Shulman HM, Anderson JE, et al: Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 95:1188, 2000.

373.
Gordon MS: Advances in supportive case of myelodysplastic syndromes. Sem Hematol 36:21, 1999.

374.
Greenberg PL, Sanz GF, Sanz MA: Prognostic scoring systems for risk assessment in myelodysplastic syndromes. Forum 9:17, 1999.

375.
Maes B, Meeus P, Michaux L, et al: Application of the International Prognostic Scoring System for myelodysplastic syndromes. J Oncol 10:825, 1999.

376.
Escudier SM, Albitar M, Robertson LE, et al: Acute lymphoblastic leukemia following preleukemic syndromes in adults. Leukemia 10:473, 1996.
Books@Ovid
Copyright © 2001 McGraw-Hill
Ernest Beutler, Marshall A. Lichtman, Barry S. Coller, Thomas J. Kipps, and Uri Seligsohn
Williams Hematology

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: